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Response to Reviewers: Reviewer #1: 
1. In two places, it is indicated that GLP-1 is used to stimulate 
cells. Change to GLP-2 
(legend to Fig. 1 and to Fig. 5)  
 
We thank the reviewer for spotting these oversights and have now 
corrected them (p 20, l 498; p 21, l 532).  
 
 
2. The quality of the figures could be improved. For instance, the 
size of the figure panels could be reduced in order to enable indications 
under the histogrammes to be correctly positioned. 
 
We have looked again at the figures and are not altogether sure we 
understand the reviewer’s point; we would be happy to edit if the 
reviewer could be more explicit about the figures that are problematical.  
 
 
3. The number of experiments performed (including in Fig.6), 
concentrations of compounds…. should be indicated in the legends.  
 
We now include additional information in the figure legends (p 21 – 23).  
 
 
4. The p values of significance should be given (It seems that all p 
values are ≤0.05). 
 
We now include further information on this point (p 21 – 23).  
 
 
 
Reviewer #2:  
1.  A major concern about the study relates to whether the lower band 
on the IGFBP-4 immunoblot is inactive with respect to IGF-1 binding. 
While the molecular weight certainly matches that of reported IGFBP-4 
degradation products, this product must also fail to bind IGF-1 in order 
for the hypothesis to be validated.  
 
With respect, we would suggest that the reviewer may be over-interpreting 
our findings. The key point is that by definition we only see those 
fragments that are recognised by the antibody. It is to be expected that 
there will be other degradation products that lack the relevant epitope 
and so are invisible in the study. We agree that it is conceivable that 
partial degradation products bind IGF-1 and -2  but there is no reason at 
the moment to assume the bands we see are the relevant ones in this 
context, and therefore merit the substantial additional work the reviewer 
proposes. On the basis of the present data we think it is reasonable to 
conclude that GLP-2 stimulates IGFBP-4 and -5 degradation in 
myofibroblast medium (which is a worthwhile observation in its own 
right), and we accept the importance of making clear that there remain 
further questions about the significance of this. We have now revised the 
Discussion (p14, l 350)to make this point clearer. Given doubts about the 
significance of any one band seen on Western blot, we think it will 
require a major study that goes far beyond the present one in order to 
determine the relative importance of IGFBP-4 compared with -5 and -7 in 
sequestering IGF-1 and -2, whether any specific IGFBP-4 or -5 band 
retains IGF-binding ability, and to determine whether any of these 
products have biological activity independent of IGF binding. Again, we 
have now made this point in the Discussion (p14).  
 
 
2.  A second major concern relates to the migration studies. 
Specifically, in the presence of a 2-3X increase in proliferation, how 
can the authors differentiate between cells being 'pushed' by 
proliferation as compared to migration independent of proliferation?  
 
The key point to understand here is that in the conditions used for 
migration studies there is little or no cell proliferation. In Boyden 
chambers for example, the migration responses are seen at periods up to 
about 24h but proliferative responses (meaning cell division) take 
longer. For the Ibidi experiments it is true that we went up to 42 h, but 
the main migration effects were already clearly evident at much earlier 
periods again before cell division would impact on the data. To avoid any 
doubt we should make it clear that although GLP-2-stimulated EdU 
incorporation can be seen at much shorter periods this only marks S-phase 
and doubling of cell numbers obviously requires completion of G2 and M 
phases as well – hence the longer time period (72 h was used for the cell 
counting kit estimates). In addition to these considerations, it should 
be noted that the Boyden chamber experiments are designed to reflect 
chemotaxis (ie migration through pores onto the lower surface of the 
insert); the cells are not confluent in the insert and proliferation in 
the absence of chemotaxis would not lead to migration through the pores. 
Finally, we would stress that the magnitude of the effect of GLP-2 
conditioned medium on epithelial cell proliferation was modest, while the 
migratory response was greater and the invasive response was substantial 
– it is difficult to see how this profile could be explained by effects 
secondary to proliferation.  
 
 
3.The authors have tested a single broad-spectrum MMP inhibitor, GM6001 - 
do they know whether this also inhibits PAPP-A, the major IGFBP-4 
degrading enzyme? If not, then this should also be tested. 
 
We chose GM6001 specifically because it was a broad-spectrum MMP 
inhibitor. There is evidence that GM6001 does not inhibit members of the 
pappalysin family and we now cite a reference on this (p 14, l 346). We 
agree that in some systems membrane-attached PAPP-A degrades IGFBP-4 
dependent on IGF binding although it degrades IGFBP-5 in a non-IGF 
dependent manner. In the context of epithelial-stromal signalling, 
however, previous proteomic studies (which we cite) have shown extensive 
degradation of IGFBP-5 by soluble MMPs, eg MMP-7, that are present in the 
microenvironment in vivo. 
 
 
4. Similarly, a single IGF-1R inhibitor was tested, AG1024, which is 
known to also inhibit the IR-TK. A second IGF-1R inhibitor should also be 
tested to demonstrate specificity of the effects. 
 
The IC50 for AG1024 at the insulin receptor is 2 – 3 fold higher than the 
concentration we used. It is extremely difficult, therefore, to see how 
the concentration we used could produce profound inhibition if the 
insulin receptor was mediating the effect. We now include an additional 
reference on the specificity of AG1024 (p 9, l 212). As it happens, the 
differential action of AG1024 on IGF compared with insulin receptors is 
favourable when set against other inhibitors and we would like to suggest 
that it is unlikely that further studies will change the conclusions of 
this study.  
 
 
5. The description of the CAM and adjacent cell models is really not 
adequate. First, have the authors validated their own cell models by 
immunostaining? Just because someone else did so does not mean that the 
same cells are being grown in another lab. In addition, the references 
cited for this model are mainly gastric, with reference to colon only 
once in one of the two papers - this increases the necessity for 
validation of these cell models in the author's lab.  
 
The papers we cited included Varro as a co-author (also a co-author of 
this manuscript), so given the shared responsibility of all authors for a 
paper, it is misleading to imply that “someone else did” the validation. 
As it happens, validation was performed in our laboratory and some 
further information is now added (p 6, l 128). It might perhaps be 
reassuring to the reviewer to know that in other microarray and proteomic 
studies we have performed (that will be published in due course) we have 
identified expression of further myofibroblast markers, for example FAP 
(seprase), in the colonic CAMs and ATMs so there is little doubt about 
the identity of these cells.    
 
 
6. The new cell models should also be validated for expression of the 
full length GLP-2R, either through a full-length PCR or via multiple 
primers directed towards several exon-intron boundaries across the length 
of this long transcript. 
 
The reviewer is, by implication, suggesting that it is implausible to 
suppose the GLP-2 receptor is expressed on the colonic myofibroblasts we 
used. As the references we cite make clear there is already evidence in 
the literature going back a decade that other fibroblasts/myofibroblasts 
express the receptor; why should it be supposed that these particular 
myofibroblasts do not express the receptor and, therefore, that the 
effects of GLP-2 we observe are mediated by a different receptor? This is 
not a parsimonious hypothesis and we would suggest it falls foul of 
Occam’s razor.  
 
 
6. Finally, there are a large number of minor points that should be 
addressed: 
- the demonstrated role of the Erb family of ligands and receptors in the 
actions of GLP-2 should be noted  
 
We agree that this point should have been documented and the revised text 
now covers this (p 4, l100).  
 
 
- n values are missing for many figures (and is there more than n=1 for 
the blots in figure 6? There should be!)  
 
We now include n values throughout the legends (p 20 – 22). 
 
 
- details are missing re the migration and invasion assays and the 
citation is not helpful in this regard - how are these differentiated, 
and were these studies performed in a blinded fashion?  
 
These are very well established assays (for example over a 100 papers 
published last year using Boyden chamber migration assay). We believe the 
details we have provided are sufficient for a qualified investigator to 
repeat the experiment (and are similar to the details we and others have 
reported in many previous papers). As is very well known, invasion assays 
employing Boyden chambers differ from migration assays in that the 
membrane is precoated with Matrigel (so migrating cells need to digest 
the extracellular matrix before they can penetrate the lower membrane). 
 
 
- there appears to be a missing statistical comparison in figure 5 (CAM, 
middle panel, 42 hr - vs + GLP-2)  
 
Many thanks for spotting this, the difference is significant and now 
indicated.  
 
 
- 
 the highlights should more clearly emphasize primary cells rather than 
just cancer colonic myofibroblasts, as some of the claims have already 
been shown for established cell lines  
 
We have edited the highlights (p 2,  l 41). 
 
 
- please cite the Cell Counting Kit-8 (CeCo) more accurately - the 
description given does not pull up any assay on the Dojindo website  
 
We regret the confusion here, although we think that Donjindo have not 
been helpful in naming this kit. The ambiguity arises because the Dojindo 
website specifically mentions “CCK8”  assays (an abbreviation for “cell 
counting kit-8”). This is potentially a cause of major confusion in a 
journal such as Peptides that publishes papers on the C-terminal 
octapeptide of cholecystokinin which has been universally abbreviated to 
CCK8 for over 40 years; indeed our laboratory has published very many 
papers on this peptide using the term “CCK8”! We hope the reviewer will 
agree therefore that it is simply not possible for us to use the 
abbreviation “CCK8” for the cell counting kit. We chose “CeCo” as an 
alternative contraction to “Cell Counting” used by Dojindo. We have now 
added a comment in the Methods that should clarify the point (p 7, l 
150).  
 
 
- IG(F)-2 is spelled incorrectly on line 53 page 10 
 
Thank you. This is now corrected. 
 
 
- while the paper does note that GLP-2 may increase cancer progression in 
rodents, it fails to note that this has not been found to date in humans 
- this is worth a caveat in the discussion 
 
We agree and have now added a point in Discussion (p 15, l 370).  
 
 
Reviewer #3:  
1. The Introduction does not really clarify why one would assume that 
GLP-2 has any role in CRC.  This is later raised in the last paragraph in 
the Discussion, but a rationale for looking at GLP-2/CAM/ATM/CRC is not 
really laid out at the beginning. A brief rationale for studying GLP-2 in 
the context of CRC is needed at the beginning. The Introduction notes 
that GLP-2 might stimulate intestinal growth, but no comment on colonic 
growth.  Is there a physiologic role for GLP-2 in colonic physiology, or 
is this only relevant in colon cancer?   
 
We have now revised the Introduction. We agree that a specific comment on 
stimulation of colonic growth is appropriate and we add a reference on 
this point (p 5, l 110).  
 
 
2. I was a bit slow in picking up what ATMs and CAMs were in the 
Results section.  I went back and saw that they were well defined at the 
beginning of the Introduction and in the Methods, but perhaps one more 
sentence defining them in the Results would help.  Maybe an additional 
explanation in the Methods about how they were isolated and grown and 
characterized, so that the reader does not have to go back to the 
literature?  Do these ATMs and CAMs express GLP-2R?   
 
We now add some extra detail in the Methods (p 6, l 127)and some 
additional material in the Results (p 9, l 200; p 9, l210). We have 
microarray data indicated the expression of GLP-2R by these cells; this 
dataset will be published as part of a more detailed study, but given 
that the capacity of myofibroblasts to express GLP2-R is not in itself 
controversial we hope this will satisfy the reviewer.  
 
 
3. Also, the point is made in the Introduction that they are 
different, which presumably why they were both studied, but no conclusion 
was provided in the Abstract or Discussion about any differences found in 
this study.  If no big differences, perhaps a sentence indicating that 
this was the case? 
 
We are happy to be more explicit on this point. We have published a 
number of previous papers that show CAMs exhibit a more aggressive 
phenotype than ATMs or normal tissue myofibroblasts (increased 
proliferation, migration, invasion etc). The present study shows the same 
is largely true for colonic myofibroblasts: Fig 1 shows CAMs exhibit 
higher basal and GLP-2-stimulated EdU incorporation than ATMs, Fig 2 
shows increased GLP-2-stimulated invasion by CAMs compared with ATMs 
(although interestingly migration was similar). We have now edited the 
Abstract (p 3, l 60), Results and Discussion (p 13, l 308) to bring out 
this point more explicitly. 
 
 
4. The study nicely shows in Figure 3 that GLP-2 is unable to 
stimulate the growth of colon cancer cell lines (SW480, HT29, LoVo).  
However, was it determined whether or not these cell lines expressed the 
GLP2 receptor?  If they do, the lack of response would be even more 
interesting, but one would guess that they do not.   
 
Koehler et al have already noted that SW480 and HT29 cells do not respond 
to GLP-2 and an examination of microarray datasets confirms that these 
and LoVo cells do not express the receptor. The relevant literature 
citation on this point are now included (p 9, l 215).   
 
 
5. Perhaps the one piece of data that would be nice to have would be 
assessment of IGF-I and IGF-2 peptide levels in the mediate in response 
to GLP-2 treatment of CAM and ATM cells.  Can this be measured by ELISA 
or RIA?  The antagonist data is strong, and GLP-2 does increase IGF-1 and 
IGF-2 mRNA abundance, perhaps this additional data is not essential, but 
reasonable to include if available.   
 
Thank you for this suggestion, unfortunately we do not have this 
information available.  
 
 
6. The data on IGFBP-4 and IGFBP-5 is quite interesting, including the 
finding of increased degradation products.  I was under the impression 
that the IGFBP's inhibit IGF signaling, but this data might also support 
the alternative hypothesis, an idea also raised by the authors and 
Reference #1 on page 14.  Is this considered a possibility - perhaps some 
suggestion about how this might be addressed further? 
 
The IGFBPs sequester IGF-1 and IGF-2 and therefore inhibit IGF 
signalling. However, it appears that they may also have their own 
biological activities (independent of IGF binding). We have revised the 
Discussion (p 14, l 350) in an attempt to avoid potential confusion; we 
completely agree with the reviewer that further work is required and we 
have added a point to this effect. 
 
 
7. The Discussion ends with a summary of GLP-2 studies in CRC and a 
cautionary note regarding GLP-2, but perhaps a better ending conclusion 
might be the role of IGF's as downstream mediators of GLP-2 effects, and 
maybe further working targeting IGF signaling in the treatment of CRC?  
 
We thank the reviewer for this suggestion and have edited this section (p 
15, l 375).   
 
 
 
 
 
 
  A member of the  
Russell Group 
 
    
  
  
The editor, Peptides 
 
 
 
 
 
21 Dec 2016 
 
 
Dear Karl, 
 
We have pleasure in submitting the attached manuscript (Glucagon-like petide-2 acts on 
colon cancer myofibroblasts to stimulate proliferation and migration of both 
myofibroblasts and cancer cells via the IGF pathway) for publication in Peptides. The 
work has not been published previously and is not under consideration by another journal. All 
the authors have approved the submitted version of the manuscript.  
 
In spite of considerable interest in the action of GLP-2 on intestinal growth, there has been 
rather little work done on its possible role in cancer and in particular on the way that GLP-2 
might modify the cancer microenvironment by acting on myofibroblasts. As far as we know 
nobody has previously studied the action of GLP-2 on cancer derived myofibroblasts.  
 
The most obviously distinguished workers in this area are Dan Drucker, Jens Holst and 
Patricia Brubaker; we think it unlikely that Dan or Jens would have sufficient time to act as 
reviewers (although we would be happy if they did): we have therefore recommended Patricia 
as a potential reviewer together with Kay Lund (who is distinguished for her work on the 
intestinal IGF system and has also worked on GLP-2 and fibroblasts), together with Yash 
Mahida (who is distinguished for his pioneering studies on gut myofibroblasts). 
 
Best wishes as ever 
 
 
 
 
Graham J Dockray FRCP (Hon), FMedSci, FRS  
 
 
 
 
 
 
 
 
 
 
Professor Graham J Dockray 
FRCP(Hon), FMedSci, FRS  
 
Physiological Laboratory 
Institute of Translational Medicine 
Crown St 
Liverpool 
L69 3BX 
UK 
 
T (44)(0)151 794 5324 
F (44)(0)151 794 5315 
E g.j.dockray@liv.ac.uk 
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  A member of the  
Russell Group 
 
    
  
  
The editor, Peptides 
 
 
 
 
 
20 Feb 2017 
 
 
Dear Karl, 
 
We have pleasure in submitting a revised version of the attached manuscript (Glucagon-like 
petide-2 acts on colon cancer myofibroblasts to stimulate proliferation, migration and 
invasion of both myofibroblasts and cancer cells via the IGF pathway) for publication in 
Peptides.  
 
We would like to thank the reviewers for their constructive comments. We have revised the 
manuscript to deal with most of the these comments, although there are a few instances where 
we have dealt with issues in our point-by-point response.  
 
 
Best wishes as ever 
 
 
 
 
Graham J Dockray FRCP (Hon), FMedSci, FRS  
 
 
 
 
 
 
 
 
 
 
 
Professor Graham J Dockray 
FRCP(Hon), FMedSci, FRS  
 
Physiological Laboratory 
Institute of Translational Medicine 
Crown St 
Liverpool 
L69 3BX 
UK 
 
T (44)(0)151 794 5324 
F (44)(0)151 794 5315 
E g.j.dockray@liv.ac.uk 
 
 
 
 
Cover Letter
Highlights 
- GLP-2  stimulates proliferation and invasion of primary colonic cancer-derived 
myofibroblasts to a greater extent than those from adjacent tissue; GLP-2 conditioned 
medium from myofibroblasts stimulated proliferation, migration and invasion of intestinal 
epithelial cells.  
- An inhibitor of IGF receptor signalling blocks the effect of GLP-2 on colonic myofibroblasts. 
- GLP-2 increases IGF-1 and -2 transcript abundance in myofibroblasts and stimulates 
degradation of IGF binding proteins in myofibroblasts medium, compatible with increased 
bioavailability of IGF.  
- GLP-2 may influence the cancer microenvironment via actions on stromal cells such as 
myofibroblasts.  
 
Highlights (for review)
Reviewer #1: 
1. In two places, it is indicated that GLP-1 is used to stimulate cells. Change to GLP-2 
(legend to Fig. 1 and to Fig. 5)  
We thank the reviewer for spotting these oversights and have now corrected them (p 20, l 498; p 
21, l 532).  
2. The quality of the figures could be improved. For instance, the size of the figure panels could 
be reduced in order to enable indications under the histogrammes to be correctly 
positioned. 
We have looked again at the figures and are not altogether sure we understand the reviewer’s 
point; we would be happy to edit if the reviewer could be more explicit about the figures that are 
problematical.  
 
3. The number of experiments performed (including in Fig.6), concentrations of compounds…. 
should be indicated in the legends.  
We now include additional information in the figure legends (p 21 – 23).  
 
4. The p values of significance should be given (It seems that all p values are ≤0.05). 
We now include further information on this point (p 21 – 23).  
 
 
 
Reviewer #2:  
1.  A major concern about the study relates to whether the lower band on the IGFBP-4 
immunoblot is inactive with respect to IGF-1 binding. While the molecular weight certainly 
matches that of reported IGFBP-4 degradation products, this product must also fail to bind 
IGF-1 in order for the hypothesis to be validated.  
With respect, we would suggest that the reviewer may be over-interpreting our findings. The key 
point is that by definition we only see those fragments that are recognised by the antibody. It is to 
be expected that there will be other degradation products that lack the relevant epitope and so 
are invisible in the study. We agree that it is conceivable that partial degradation products bind 
IGF-1 and -2  but there is no reason at the moment to assume the bands we see are the relevant 
ones in this context, and therefore merit the substantial additional work the reviewer proposes. On 
the basis of the present data we think it is reasonable to conclude that GLP-2 stimulates IGFBP-4 
and -5 degradation in myofibroblast medium (which is a worthwhile observation in its own right), 
*Detailed Response to Reviewers
and we accept the importance of making clear that there remain further questions about the 
significance of this. We have now revised the Discussion (p14, l 350)to make this point clearer. 
Given doubts about the significance of any one band seen on Western blot, we think it will require 
a major study that goes far beyond the present one in order to determine the relative importance 
of IGFBP-4 compared with -5 and -7 in sequestering IGF-1 and -2, whether any specific IGFBP-4 or -
5 band retains IGF-binding ability, and to determine whether any of these products have biological 
activity independent of IGF binding. Again, we have now made this point in the Discussion (p14).  
 
2.  A second major concern relates to the migration studies. Specifically, in the presence of a 2-
3X increase in proliferation, how can the authors differentiate between cells being 'pushed' 
by proliferation as compared to migration independent of proliferation?  
The key point to understand here is that in the conditions used for migration studies there is little 
or no cell proliferation. In Boyden chambers for example, the migration responses are seen at 
periods up to about 24h but proliferative responses (meaning cell division) take longer. For the 
Ibidi experiments it is true that we went up to 42 h, but the main migration effects were already 
clearly evident at much earlier periods again before cell division would impact on the data. To 
avoid any doubt we should make it clear that although GLP-2-stimulated EdU incorporation can be 
seen at much shorter periods this only marks S-phase and doubling of cell numbers obviously 
requires completion of G2 and M phases as well – hence the longer time period (72 h was used for 
the cell counting kit estimates). In addition to these considerations, it should be noted that the 
Boyden chamber experiments are designed to reflect chemotaxis (ie migration through pores onto 
the lower surface of the insert); the cells are not confluent in the insert and proliferation in the 
absence of chemotaxis would not lead to migration through the pores. Finally, we would stress 
that the magnitude of the effect of GLP-2 conditioned medium on epithelial cell proliferation was 
modest, while the migratory response was greater and the invasive response was substantial – it is 
difficult to see how this profile could be explained by effects secondary to proliferation.  
 
3.The authors have tested a single broad-spectrum MMP inhibitor, GM6001 - do they know 
whether this also inhibits PAPP-A, the major IGFBP-4 degrading enzyme? If not, then this 
should also be tested. 
We chose GM6001 specifically because it was a broad-spectrum MMP inhibitor. There is evidence 
that GM6001 does not inhibit members of the pappalysin family and we now cite a reference on 
this (p 14, l 346). We agree that in some systems membrane-attached PAPP-A degrades IGFBP-4 
dependent on IGF binding although it degrades IGFBP-5 in a non-IGF dependent manner. In the 
context of epithelial-stromal signalling, however, previous proteomic studies (which we cite) have 
shown extensive degradation of IGFBP-5 by soluble MMPs, eg MMP-7, that are present in the 
microenvironment in vivo. 
4. Similarly, a single IGF-1R inhibitor was tested, AG1024, which is known to also inhibit the IR-
TK. A second IGF-1R inhibitor should also be tested to demonstrate specificity of the effects. 
The IC50 for AG1024 at the insulin receptor is 2 – 3 fold higher than the concentration we used. It is 
extremely difficult, therefore, to see how the concentration we used could produce profound 
inhibition if the insulin receptor was mediating the effect. We now include an additional reference 
on the specificity of AG1024 (p 9, l 212). As it happens, the differential action of AG1024 on IGF 
compared with insulin receptors is favourable when set against other inhibitors and we would like 
to suggest that it is unlikely that further studies will change the conclusions of this study.  
5. The description of the CAM and adjacent cell models is really not adequate. First, have the 
authors validated their own cell models by immunostaining? Just because someone else did 
so does not mean that the same cells are being grown in another lab. In addition, the 
references cited for this model are mainly gastric, with reference to colon only once in one 
of the two papers - this increases the necessity for validation of these cell models in the 
author's lab.  
The papers we cited included Varro as a co-author (also a co-author of this manuscript), so given 
the shared responsibility of all authors for a paper, it is misleading to imply that “someone else 
did” the validation. As it happens, validation was performed in our laboratory and some further 
information is now added (p 6, l 128). It might perhaps be reassuring to the reviewer to know that 
in other microarray and proteomic studies we have performed (that will be published in due 
course) we have identified expression of further myofibroblast markers, for example FAP (seprase), 
in the colonic CAMs and ATMs so there is little doubt about the identity of these cells.    
6. The new cell models should also be validated for expression of the full length GLP-2R, either 
through a full-length PCR or via multiple primers directed towards several exon-intron 
boundaries across the length of this long transcript. 
The reviewer is, by implication, suggesting that it is implausible to suppose the GLP-2 receptor is 
expressed on the colonic myofibroblasts we used. As the references we cite make clear there is 
already evidence in the literature going back a decade that other fibroblasts/myofibroblasts 
express the receptor; why should it be supposed that these particular myofibroblasts do not 
express the receptor and, therefore, that the effects of GLP-2 we observe are mediated by a 
different receptor? This is not a parsimonious hypothesis and we would suggest it falls foul of 
Occam’s razor.  
 
6. Finally, there are a large number of minor points that should be addressed: 
- the demonstrated role of the Erb family of ligands and receptors in the actions of GLP-2 should be 
noted  
We agree that this point should have been documented and the revised text now covers this (p 4, 
l100).  
- n values are missing for many figures (and is there more than n=1 for the blots in figure 6? There 
should be!)  
We now include n values throughout the legends (p 20 – 22). 
- details are missing re the migration and invasion assays and the citation is not helpful in this regard 
- how are these differentiated, and were these studies performed in a blinded fashion?  
These are very well established assays (for example over a 100 papers published last year using 
Boyden chamber migration assay). We believe the details we have provided are sufficient for a 
qualified investigator to repeat the experiment (and are similar to the details we and others have 
reported in many previous papers). As is very well known, invasion assays employing Boyden 
chambers differ from migration assays in that the membrane is precoated with Matrigel (so 
migrating cells need to digest the extracellular matrix before they can penetrate the lower 
membrane). 
 
- there appears to be a missing statistical comparison in figure 5 (CAM, middle panel, 42 hr - vs + 
GLP-2)  
Many thanks for spotting this, the difference is significant and now indicated.  
- 
 the highlights should more clearly emphasize primary cells rather than just cancer colonic 
myofibroblasts, as some of the claims have already been shown for established cell lines  
We have edited the highlights (p 2,  l 41). 
 
- please cite the Cell Counting Kit-8 (CeCo) more accurately - the description given does not pull up 
any assay on the Dojindo website  
We regret the confusion here, although we think that Donjindo have not been helpful in naming 
this kit. The ambiguity arises because the Dojindo website specifically mentions “CCK8”  assays (an 
abbreviation for “cell counting kit-8”). This is potentially a cause of major confusion in a journal 
such as Peptides that publishes papers on the C-terminal octapeptide of cholecystokinin which has 
been universally abbreviated to CCK8 for over 40 years; indeed our laboratory has published very 
many papers on this peptide using the term “CCK8”! We hope the reviewer will agree therefore 
that it is simply not possible for us to use the abbreviation “CCK8” for the cell counting kit. We 
chose “CeCo” as an alternative contraction to “Cell Counting” used by Dojindo. We have now 
added a comment in the Methods that should clarify the point (p 7, l 150).  
- IG(F)-2 is spelled incorrectly on line 53 page 10 
Thank you. This is now corrected. 
- while the paper does note that GLP-2 may increase cancer progression in rodents, it fails to note 
that this has not been found to date in humans - this is worth a caveat in the discussion 
We agree and have now added a point in Discussion (p 15 , l 370).  
 
 Reviewer #3:  
1. The Introduction does not really clarify why one would assume that GLP-2 has any 
role in CRC.  This is later raised in the last paragraph in the Discussion, but a 
rationale for looking at GLP-2/CAM/ATM/CRC is not really laid out at the 
beginning. A brief rationale for studying GLP-2 in the context of CRC is needed at 
the beginning. The Introduction notes that GLP-2 might stimulate intestinal 
growth, but no comment on colonic growth.  Is there a physiologic role for GLP-2 
in colonic physiology, or is this only relevant in colon cancer?   
We have now revised the Introduction. We agree that a specific comment on stimulation of colonic 
growth is appropriate and we add a reference on this point (p 5, l 110).  
 
2. I was a bit slow in picking up what ATMs and CAMs were in the Results section.  I 
went back and saw that they were well defined at the beginning of the 
Introduction and in the Methods, but perhaps one more sentence defining them 
in the Results would help.  Maybe an additional explanation in the Methods 
about how they were isolated and grown and characterized, so that the reader 
does not have to go back to the literature?  Do these ATMs and CAMs express 
GLP-2R?   
We now add some extra detail in the Methods (p 6, , l 127)and some additional material in the 
Results (p 9 , l 200; p 9, l210). We have microarray data indicated the expression of GLP-2R by 
these cells; this dataset will be published as part of a more detailed study, but given that the 
capacity of myofibroblasts to express GLP2-R is not in itself controversial we hope this will satisfy 
the reviewer.  
3. Also, the point is made in the Introduction that they are different, which presumably 
why they were both studied, but no conclusion was provided in the Abstract or 
Discussion about any differences found in this study.  If no big differences, 
perhaps a sentence indicating that this was the case? 
We are happy to be more explicit on this point. We have published a number of previous papers 
that show CAMs exhibit a more aggressive phenotype than ATMs or normal tissue myofibroblasts 
(increased proliferation, migration, invasion etc). The present study shows the same is largely true 
for colonic myofibroblasts: Fig 1 shows CAMs exhibit higher basal and GLP-2-stimulated EdU 
incorporation than ATMs, Fig 2 shows increased GLP-2-stimulated invasion by CAMs compared 
with ATMs (although interestingly migration was similar). We have now edited the Abstract (p 3, l 
60), Results and Discussion (p 13, l 308) to bring out this point more explicitly. 
4. The study nicely shows in Figure 3 that GLP-2 is unable to stimulate the growth of 
colon cancer cell lines (SW480, HT29, LoVo).  However, was it determined 
whether or not these cell lines expressed the GLP2 receptor?  If they do, the lack 
of response would be even more interesting, but one would guess that they do 
not.   
Koehler et al have already noted that SW480 and HT29 cells do not respond to GLP-2 and an 
examination of microarray datasets confirms that these and LoVo cells do not express the 
receptor. The relevant literature citation on this point are now included (p 9, l 215).   
5. Perhaps the one piece of data that would be nice to have would be assessment of 
IGF-I and IGF-2 peptide levels in the mediate in response to GLP-2 treatment of 
CAM and ATM cells.  Can this be measured by ELISA or RIA?  The antagonist data 
is strong, and GLP-2 does increase IGF-1 and IGF-2 mRNA abundance, perhaps 
this additional data is not essential, but reasonable to include if available.   
Thank you for this suggestion, unfortunately we do not have this information available.  
6. The data on IGFBP-4 and IGFBP-5 is quite interesting, including the finding of 
increased degradation products.  I was under the impression that the IGFBP's 
inhibit IGF signaling, but this data might also support the alternative hypothesis, 
an idea also raised by the authors and Reference #1 on page 14.  Is this 
considered a possibility - perhaps some suggestion about how this might be 
addressed further? 
The IGFBPs sequester IGF-1 and IGF-2 and therefore inhibit IGF signalling. However, it appears that 
they may also have their own biological activities (independent of IGF binding). We have revised 
the Discussion (p 14, l 350) in an attempt to avoid potential confusion; we completely agree with 
the reviewer that further work is required and we have added a point to this effect. 
7. The Discussion ends with a summary of GLP-2 studies in CRC and a cautionary note 
regarding GLP-2, but perhaps a better ending conclusion might be the role of 
IGF's as downstream mediators of GLP-2 effects, and maybe further working 
targeting IGF signaling in the treatment of CRC?  
 
We thank the reviewer for this suggestion and have edited this section (p 15, l 375).   
 
 
 
 
 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
Shawe-Taylor, page 1 
 
Glucagon-like petide-2 acts on colon cancer myofibroblasts to stimulate proliferation 
and migration of both myofibroblasts and cancer cells via the IGF pathway 
 
Marianne Shawe-Taylor, J. Dinesh Kumar, Whitney Holden, Steven Dodd, Akos Varga, 
Olivier Giger, Andrea Varro, Graham J. Dockray 
 
Department of Cellular and Molecular Physiology, Institute of Translational Medicine, 
University of Liverpool, Liverpool UK. 
 
Short title: GLP-2 actions on colonic myofibroblasts 
 
Key words: GLP-2, IGF, IGFBP, myofibroblast migration, proliferation. 
 
 
Address correspondence to: 
Graham Dockray 
Department of Cell and Molecular Physiology 
Institute of Translational Medicine 
University of Liverpool 
Crown St 
Liverpool 
L69 3BX 
UK 
 
Email: g.j.dockray@liverpool.ac.uk  
Tel: (00)(44)151 794 5324 
   
*Manuscript
Click here to download Manuscript: GLP2~12~20~16FINAL.doc Click here to view linked References
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
Shawe-Taylor, page 2 
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myofibroblasts; GLP-2, glucagon-like peptide 2; IGF, insulin-like growth factor; IGFBP, 
insulin-like growth factor binding protein; MMP, matrix metalloproteinase.  
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Highlights 
- GLP-2  stimulates the migration and proliferation of colonic cancer myofibroblasts as 
well as intestinal epithelial cells.  
- An inhibitor of IGF receptor signalling blocks the effect of GLP-2 on colonic 
myofibroblasts. 
- GLP-2 increases IGF-1 and -2 transcript abundance in myofibroblasts and stimulates 
degradation of IGF binding proteins in myofibroblasts medium, leading to increased 
bioavailability of IGF.  
- GLP-2 may influence the cancer microenvironment via actions on stromal cells such 
as myofibroblasts.  
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Abstract  
Glucagon-like peptide (GLP)-2 stimulates intestinal epithelial proliferation by acting, in part, 
via IGF release from sub-epithelial myofibroblasts. The response of myofibroblasts to GLP-2 
remains incompletely understood. We studied the action of GLP-2 on myofibroblasts from 
colon cancer and adjacent tissue, and the effects of conditioned medium from these cells on 
epithelial cell migration and proliferation. In response to GLP-2, myofibroblasts from cancer 
and adjacent tissue exhibited increased proliferation, migration and invasion; these 
responses were inhibited by the IGF receptor inhibitor, AG1024. Conditioned medium from 
GLP-2 treated myofibroblasts increased proliferation, migration and invasion of SW480, 
HT29, LoVo epithelial cells and these responses were inhibited by AG1024; GLP-2 alone 
had no effect on these cells.  In addition, when myofibroblasts and epithelial cells were co-
cultured in Ibidi chambers there was mutual stimulation of migration in response to GLP-2. 
The latter increased both IGF-1 and IGF-2 transcript abundance in myofibroblasts. 
Moreover, a number of IGF binding proteins (IGFBP-4, -5, -7) were identified in 
myofibroblast medium and in the presence of GLP-2 there was increased abundance of the 
cleavage products of these proteins suggesting activation of a degradation mechanism 
increasing IGF bioavailability. The data suggest that GLP-2 stimulates cancer myofibroblast 
proliferation and migration; GLP-2 acts indirectly on epithelial cells partly via increased IGF 
expression in myofibroblasts and partly by increased bioavailability through degradation of 
IGFBPs.    
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Introduction 
Mucosal morphology throughout the gastrointestinal tract is determined by interactions 
between epithelial cells and underlying stromal cells which release a variety of growth 
factors [26]. These interactions are also a feature of tumour growth where it is now clear that 
stromal cells provide a supportive and stimulatory niche for cancer cells [11, 27]. A key 
stromal cell type is the myofibroblast which physiologically lies in close proximity to the basal 
membrane of epithelial cells while in cancer these cells are an important component of the 
stroma that may constitute a high proportion of tumour volume. There is now clear evidence 
that cancer-associated myofibroblasts (CAMs, often considered to be a subset of cancer-
associated fibroblasts) are functionally distinct from myofibroblasts recovered from tissue 
adjacent to the tumour (ATMs), and from normal tissue [13, 14].  
 
A range of hormonal signals from epithelial enteroendocrine cells (EECs) influence growth of 
the gastrointestinal tract, including gastrin, cholecystokinin and glucagon-like peptide (GLP)-
2. The latter is generated from the glucagon precursor by post-translational cleavage; there 
are different patterns of processing in pancreatic alpha-cells and L-cells of the ileum and 
colon. In particular, the main products in L-cells are GLP-2, GLP-1 (which is an insulin 
secretagogue) and oxyntomodulin (which is a C-terminally extended variant of glucagon). A 
link between glucagon gene expression and intestinal hypertrophy has been known for 
several decades, and it is now recognised that GLP-2 is a crucial mediator [7]. Interestingly, 
GLP-2 receptors are not expressed on intestinal epithelial cells, with the possible exception 
of some EECs, and as a consequence GLP-2 does not have direct effects on intestinal 
epithelial cell proliferation. Instead there is evidence that GLP-2 acts indirectly via sub-
epithelial cells notably myofibroblasts and neurons [2, 4, 8, 25]. Thus, the evidence suggests 
that GLP-2 releases growth factors such as IGF, KGF and VEGF-A which in turn act on 
epithelial cells to stimulate cell proliferation [5, 9, 25]. 
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Gene array data indicate that a wide variety of gastrointestinal myofibroblasts produce both 
IGF-1 and IGF-2 as well as a number of IGF binding proteins (IGFBPs) including -3, -4, -5, -
6 and -7 [3]. The IGFBPs act to sequester extracellular IGF which can be liberated by IGFBP 
cleavage, for example by matrix metalloproteinase (MMP)-7 produced by epithelial cells [12]. 
In the upper gastrointestinal tract, the IGFs act on both epithelial cells and the myofibroblasts 
themselves to stimulate proliferation as well as migration and invasion. The response of 
intestinal myofibroblasts to GLP-2 (aside from release of IGF) remains uncertain. While there 
have been studies using a CCD18 myofibroblast cell line, which is derived from normal 
intestine of a human infant, the possible effects of GLP-2 on cancer myofibroblasts are 
unclear. In the present study we have examined the hypothesis that GLP-2 acts on 
myofibroblasts from colon cancer and adjacent tissue to influence colon cancer cells lines, 
and have examined the role of IGF in mediating these effects.  
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Materials and Methods 
 
Cells. Colon cancer cells (HT29, Lovo, SW480) and CCD18 colonic myofibroblasts were 
obtained from American type culture collection (VA, US). Colonic cancer derived 
myofibroblasts (CAMs) had been generated from tumour and adjacent tissue (ATMs) of a 
patient with colon cancer using previously described methods; they have been shown to be 
positive for -smooth muscle actin and vimentin and negative for desmin  [19]. Colon cancer 
cells and myofibroblasts were cultured as previously described [14].  
 
Conditioned media. Myofibroblasts (1.5 x 106 cells) were plated in T-75 falcon flasks and 
maintained at 37oC in a 5% v/v CO2 atmosphere for 24h in full media (FM). Cultures were 
then washed 3 times with sterile PBS and incubated in 15ml serum free (SF) media with or 
without GLP-2 (AnaSpec, Freemont, CA, USA) for 24h. Conditioned medium (CM) was 
collected, centrifuged (7 min, 800 x g, 4oC) and aliquots were stored at -80oC until further 
use. 
 
EdU incorporation and cell Counting Kit-8 assays 
For EdU incorporation assays, colonic myofibroblasts and colon cancer cells (2.5x104 per 
well) were seeded and incubated overnight in FM followed by serum starvation for 48 h. 
Cells then were treated with GLP-2 or CM as appropriate for 24h. Proliferation was assessed 
by incorporation of 5-ethynyl-2’-deoxyuridine (EdU, 10 µM, 16h) and processing of samples 
using Click-iT (Invitrogen, Paisley, UK) and Alexa 568-azide. EdU positive cells were 
visualised on a Zeiss AxioCam HRM fluorescence microscope (Carl Zeiss, Welwyn Garden 
City, UK) on a 40x objective lens counting the total number of cell nuclei in 10 different fields 
using DAPI (Vector Laboratories, Peterborough, UK) (blue) and EdU positive nuclei.  
Cell Counting Kit-8 (CeCo)(Dojindo Laboratories, Munich, Germany) assays on colonic 
myofibroblasts and cancer cells (8x103 per well) were performed in 96 well plates on cells 
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incubated overnight in FM followed by incubation with GLP-2 or CM medium in phenol red 
free SF medium for 72h. On the last day 10µl CeCo reagent was added to the wells and 
incubated for 2-4h as optimised for each cell type. Readings were taken at 450nm using a 
GenioPlus plate reader (Tecan, Zurich, Switzerland). 
 
Cell migration and invasion assays. Transwell migration and invasion assays were 
performed using BD inserts (Corning, New York, USA) as previous described (2.5 x 104 cells 
per insert) [31]. GLP-2 or CM were added in the lower well together with AG1024 
(Calbiochem, Darmstadt, Germany) as appropriate. Ibidi chamber (Ibidi GmbH, Martinsried, 
Germany) migration assays were performed in 24 well plates. Ibidi culture inserts were 
placed at the bottom of the wells followed by seeding of 105 cancer cells and 5x104 
myofibroblasts on separate sides of the insert. After 24h the insert was removed, leaving a 
500µm wound; cells were then treated with GLP-2 up to 42h and images taken with a 
Hamamatsu Camera (Hamamatsu Photonics, Hamamatsu City, Japan) at 0, 6, 24, 32, 42h 
using a Leica DMIRE2 microscope on a heated stage, humidified chamber (Solent Scientific, 
Portsmouth, UK); cells in the wound were counted in 5-8 fields per insert. 
 
qPCR. RNA was extracted in 1.25 ml Tri-Reagent (Sigma, Dorset, UK) according to the 
manufacturer’s instructions from control and GLP-2 treated colonic myofibroblasts. RNA 
pellets were re-suspended in 50 l of nuclease free water and 4 µg of RNA reverse 
transcribed with avian myeloblastosis virus reverse transcriptase and oligo-dT primers 
(Promega). Real time PCR was carried out using an ABI7500 platform (Applied Biosystems, 
Warrington, UK) using TaqMan primer/probe sets (human IGF-1, IGF-2, GAPDH), Precision 
Plus 2x real time PCR master mix (Primer Design, Southampton, UK) and 5’-FAM, 3’-
TAMRA double dye probes (Eurogentec, Southampton, UK). All values were standardized to 
GAPDH. Assays included a no template control (NTC), and a standard curve as previously 
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described [22]. Primers and probes were designed using Primer Express v3.0 (Applied 
Biosystems) and were purchased from Eurogentec (Seraing, Belgium). Probes for detection 
of human GAPDH, IGF-1 and IGF-2 cDNA were intron-spanning and were: GAPDH: 5’-GCT 
CCT CCT GTT CGA CAG TCA-3’(forward), 5’-ACC TTC CCC ATG GTG TCT GA-3’ 
(reverse),  5’-CGT CGC CAG CCG AGC CAC A-3’ (probe); IGF-1: 5’-TGT ATT GCG CAC 
CCC TCA A-3’ (forward), 5’-CT CCC TCT ACT TGC GTT CTT CA-3’ (reverse), 5’-ACA TGC 
CCA AGA CCC AGA AGG AAG TAC A-3’ (probe); IGF-2, 5’-CCG TGC TTC CGG ACA ACT 
T-3’ (forward), 5’-GGA CTG CTT CCA GGT GTC ATA TT-3’ (reverse), 5’-CCC AGA TAC 
CCC GTG GGC AAG TTC-3’ (probe). 
 
Western blotting. Cell extracts were prepared in RIPA buffer and media samples were 
concentrated with StrataClean resins (Agilent Technologies Ltd, Santa Clara, CA, USA) and 
processed for Western blotting as previously described  [22] using antibodies to IGFBP-3, 4, 
5 and -7, MMP-1, -2, -3 and -10 (R&D Systems) and GAPDH (Biodesign, Maine, USA). 
 
Statistics. Results were calculated as mean ± standard error of means (SEM). Student t-
test and ANOVA were performed on the data as appropriate with significance at p<0.05 
using Systat Software Inc. (London, UK) unless otherwise stated.  
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Results 
GLP-2 stimulates myofibroblast proliferation. In initial studies we showed that GLP-2 
produced a dose-related increase in EdU incorporation into CCD18 myofibroblasts (Fig 
1A,B). We then showed GLP-2 also stimulated EdU incorporation by both colonic CAMs and 
ATMs although basal and stimulated incorporation was greater in the CAMs (Fig 1C). In a 
CeCo assay of cell growth, GLP-2 also stimulated both CAM and ATM growth (Fig 1D). 
 
GLP-2 stimulates myofibroblast migration and invasion. We then examined the actions 
of GLP-2 on CAM and ATM migration and invasion using Boyden chambers (Fig 2A,B). In 
both cell types, GLP-2 at a concentration that stimulated proliferation also stimulated 
migration and these responses were abolished by the inhibitor of IGF receptor tyrosine 
kinase, AG1024. Similarly there was IGF-dependent stimulation of invasion although the 
CAM response was significantly greater than that of ATMs. 
 
Myofibroblast conditioned medium stimulates epithelial cell proliferation. There was 
no change in EdU incorporation (Fig 3A) by two of the epithelial cell lines used in the present 
study (SW480 and LoVo) in response to GLP-2 applied directly to the cells; there was a 
small effect on HT29 cells (Fig 3B). In the case of SW480 cells there was a small increase in 
EdU incorporation in response to CAM CM that was enhanced by pre-treatment of 
myofibroblasts with GLP-2; there were greater increases in EdU incorporation by HT29 and 
LoVo cells in response to CAM CM, and in both cases there were small further increases 
using CM from GLP-2-treated myofibroblasts. In all three intestinal cell lines, the responses 
to control CM and to GLP-2 CM were suppressed by AG1024 (Fig 3C). In CeCo assays of 
cell growth, there were robust responses by all three intestinal epithelial lines to control 
myofibroblast CM and small but significantly increases in response to GLP-2 pretreatment of 
myofibroblasts (Fig 3D).  
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Myofibroblast conditioned medium stimulates epithelial cell migration and invasion. 
When GLP-2 was applied directly to epithelial cells (SW480, HT29, LoVo) there was no 
effect on migration or invasion in Boyden chambers (Fig 4A). However, there was strong 
stimulation of migration of all three cell lines in response to control CAM CM and there were 
small but significant further increases in response to CM from GLP-2 treated myofibroblasts 
(Fig 4B). In each case the response was inhibited by AG1024. There were relatively modest 
increases in invasion of HT29 and LoVo cells in response to control myofibroblast CM but 
the response was strongly enhanced by GLP-2-treated CM; all responses were inhibited by 
AG1024 (Fig 4C). 
 
GLP-2 stimulates migration in co-cultures of epithelial cells and myofibroblasts. In 
view of the potential for cross-talk between epithelial cells and myofibroblasts we then asked 
whether the response to GLP-2 was preserved when these cells were co-cultured. For this 
purpose we used Ibidi chambers with myofibroblasts in one chamber and epithelial cells in 
the other so that subsequent removal of the insert yielded cultures of the two cells separated 
by 500 m (Fig 5A). Over a period of 42 h after removing the insert there was progressive 
migration of both cell types toward each other (Fig 5A). The numbers of migrating epithelial 
cells were roughly 10 times higher than those of myofibroblasts. Nevertheless at each time 
point examined from 6 – 42 h the presence of GLP-2 increased the migration of each of the 
epithelial cell lines and of the co-cultured CAMs (Fig 5B). 
 
GLP-2 increases IGF-1 and IGF-2 transcript abundance. In view of the evidence that 
GLP-2 might act via IGF we first examined microarray data from myofibroblasts which 
indicated that both IGF-1 and IG-2 were expressed in colonic CAMs and ATMs; the relative 
abundance of IGF-1 in colonic myofibroblasts was higher compared to IGF-2, while in gastric 
myofibroblasts IGF-2 was dominant [3]. We then used qPCR for both IGF-1 and IGF-2 to 
assess responses to GLP-2. At a concentration of GLP-2 (10 nM) that increased 
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myofibroblast migration and proliferation, there was 1.8 ± 0.2 fold higher IGF-1 transcript 
abundance and 1.5 ± 0.2 fold higher IGF-2 transcript abundance.  
 
GLP-2 promotes IGFBP degradation in myofibroblasts medium. Since there is evidence 
that GLP-2 might act via IGFBP-4 [1] we examined by Western blot the profile of IGFBP-4 
and also of IGFBP-3, -5 and -7 in CAMs treated with GLP-2. In control media there were 
clear bands corresponding to intact IGFBP-4, -5 and -7 (Fig 6A), while IGFBP-3 was 
undetectable (not shown). There were also minor bands corresponding to degradation 
products of IGFBP4 (15 kD) and  IGFBP-5 (10-15 kD). In the presence of GLP-2 the bands 
corresponding to intact IGFBP-4, and -5 were maintained but there was increased 
abundance of the degradation products. In the presence of an inhibitor of MMP activity 
(GM6001, 10 M) the action of GLP-2 in promoting degradation of IGFBP4 and -5 was 
inhibited (Fig 6A). There was also an increase in IGFBP-4 and -5 in cell extracts in response 
to GLP-2 compatible with increased expression (Fig 6B). Multiple proMMPs are secreted by 
myofibroblasts (MMP-1, -2, -3 and -10) [13]. Of these, MMP-1 was increased in abundance 
in GLP-2 treated cells and media (Fig 6C,D) although there was little or no change in MMP-
2, -3 and -10. 
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Discussion 
The present study provides evidence that GLP-2 acts on cancer-derived myofibroblasts to 
stimulate their proliferation, migration and invasion. The latter effects are blocked by an 
inhibitor of IGF1 receptor tyrosine kinase and since there is an increase in IGF-1 and -2 
transcript abundance as well as increased degradation of IGFBP-4 and -5, the data support 
the idea that the actions of GLP-2 on myofibroblasts are at least partly mediated by IGF. 
Consistent with previous findings, GLP-2 had little or no effect on three intestinal epithelial 
cell lines, but conditioned medium from CAMs stimulated proliferation, migration and 
invasion of these cells, and to varying degrees GLP-2 treatment of myofibroblasts enhanced 
the responses in an IGF-receptor dependent mechanism. The data add to previous work in 
this area by indicating (a) that GLP-2 might regulate myofibroblast numbers and motility, and 
(b) that myofibroblasts in cancer are putative targets for GLP-2. In view of the importance of 
myofibroblasts in determining the tumour microenvironment the data raise the prospect that 
GLP-2 might influence cancer progression.  
 
The importance of myofibroblasts as targets for the trophic action of GLP-2 in the intestine 
has been clear for some time [5, 25]. Previous work has made use of CCD18 myofibroblasts 
that are derived from normal infant intestine [5], mixed intestinal cell cultures [9] and 
intestinal sub-epithelial fibroblasts [23]. The present findings extend these studies to include 
myofibroblasts derived from colon cancer and adjacent tissue. For the most part previous 
studies have focussed on the mechanisms by which myofibroblasts influence epithelial cell 
growth. While the growth factor responses of the myofibroblasts themselves have received 
attention, less has been given to other aspects of myofibroblasts biology. The observation 
that GLP-2 increases myofibroblast cell number, and very likely cell position (via actions on 
migration/invasion), suggests a more dynamic system than previously supposed.  
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It is recognised that cancer-derived fibroblasts and myofibroblasts differ from their 
counterparts in normal tissue [6, 14, 24]. The different properties of CAMs may, at least to 
some extent, reflect epigenetic changes [17]. The fact that these cells retain the ability to 
respond to GLP-2 provides a mechanism by which GLP-2 might influence cancer 
progression [18]. The therapeutic value of GLP-2 in treatment of short bowel syndrome is 
now widely appreciated, but it would be as well to keep in mind that in some circumstances 
GLP-2 might have deleterious effects in influencing cellular microenvironments. A 
particularly clear example is provided by gastrointestinal stromal tumours that have been 
reported to express GLP-2R [21]; the possibility that GLP-2 may also act on colon cancers 
via their stromal component should now be considered.  
 
A number of growth factors have been proposed to mediate the actions of GLP-2 on 
myofibroblasts, including IGF [23], VEGF-A [5] and KGF [25]. It is important to be clear that 
these need not be mutually exclusive; nevertheless the evidence is particularly strong for a 
role for the IGF system. Our data suggest that colonic CAMs stimulate epithelial cell growth, 
migration and invasion by an IGF-receptor dependent mechanism [29] that is enhanced to 
varying degrees by treatment of myofibroblasts with GLP-2. The increase in epithelial 
proliferation was modest, the migratory response was stronger and the invasive responses 
in two cells lines were very strong. High constitutive expression of IGF has already been 
reported [23] and would account for the present findings on intestinal epithelial cell 
proliferation and migration. In the case of the strong invasion response of these cells we 
suggest that increased bioavailability of IGF as well as increased MMP-activity [13] might 
interact to enhance the response.  
 
There was increased transcript abundance of IGF-1 and IGF-2 in response to GLP-2 which 
would provide one mechanism to account for the biological responses of both epithelial cells 
and myofibroblasts. However, our data suggest that there are also likely to be other 
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mechanisms. Secreted IGF is sequestered by IGFBPs. In gastrointestinal myofibroblasts the 
main IGFBPs include IGFBP-4, -5 and -7. Cleavage of IGFBP-5 by MMP-7 released by 
epithelial cells has previously been shown to increase the bioavailability of IGF-2 which may 
stimulate both epithelial and stromal cells [12]. In addition to regulating IGF bioavailability, 
some IGFBPs or their fragments, may exert independent biological activities [10, 15]. 
Recently, a role for IGFBP-4 in mediating the effects of GLP-2 was indicated by the 
observation that in mice null for IGFBP-4 the effect of GLP-2 was inhibited [1]. The precise 
cellular mechanisms remain uncertain, but it is interesting that in our studies GLP-2 
treatment of myofibroblasts increased the abundance of IGFBP-4 degradation products seen 
in western blot; there was a similar effect on IGFBP-5 but not IGFBP-7.  Moreover, there 
was an increase in cellular abundance of IGFBP-4 and -5 compatible with stimulation of 
expression by GLP-2 as previously reported [1]. The GLP-2 stimulated degradation of 
IGFBP-4 and -5 was blocked by a broad spectrum inhibitor of MMP activity; in addition, GLP-
2 increased the abundance in media and cell extracts of proMMP-1 (although not proMMP-2, 
-3 and -10). We suggest therefore, that GLP-2 increases the expression in myofibroblasts of 
IGFBP-4 and -5, and proMMP-1, and that following secretion there is increased 
bioavailability of IGF through MMP-mediated degradation of its binding proteins.  
 
The maintenance of tissue architecture is presumed to involve two-way interactions in vivo 
between myofibroblasts and epithelial cells. We attempted to design a simple in vitro model 
to establish whether the actions of GLP-2 on myofibroblasts, and those of myofibroblasts on 
epithelial cells, were preserved when the two cell types were in co-culture. The data 
obtained using Ibidi chambers indicate that the migratory responses observed when the two 
cells were cultured separately were preserved in co-cultures. Interestingly, though, the 
magnitude of the migratory responses by epithelial cells was considerably greater than that 
of myofibroblasts. Nevertheless the data allow us to conclude that any feedback mechanism 
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from intestinal cells that might exist to limit the myofibroblast response to GLP-2 is relatively 
modest. 
 
Alongside an appreciation of the therapeutic benefits of GLP-2, there has also been an 
appreciation that GLP-2 might have growth promoting effects with deleterious consequences 
in cancer [28]. In two mouse models of carcinogen-induced colon cancer (dimethylhydrazine, 
azoxymethane) administration of GLP-2 increased tumour size [16, 30], although in other 
models eg APCmin-/- mice, it had no effect [20]. Taken as a whole the present data raise the 
prospect that GLP-2 acts on colon cancer-derived myofibroblasts to trigger pathways 
influencing myofibroblast number and motility, as well as their secretion of growth factors 
and MMPs that exacerbate cancer cell responses. The potential of GLP-2 to aggravate 
human colon cancer progression should therefore be kept under review.  
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Legends 
Fig 1. GLP-1 stimulates myofibroblast proliferation. A, Representative image of EdU labelled 
myofibroblast (filled arrow; unlabelled cells, open arrows). B, dose-response relationship for 
GLP-2 stimulation of EdU incorporation by CCD-18 cells. C, GLP-2 (10 nM) stimulates EdU 
incorporation into both cancer-derived myofibroblasts (CAM) and adjacent tissue 
myofibroblasts (ATM). D, GLP-2 also increases cell growth measured by CeCo assay. 
Horizontal arrows, p<0.05, ANOVA or t test.  
 
Fig 2. Stimulation of myofibroblast migration by GLP-2. A, GLP-2 (10nM) increases migration 
of both CAMs and ATMs in Boyden chamber chemotaxis assays and the response is 
reversed by an inhibitor of IGF1 receptor tyrosine kinase (AG1024, 2μM). B, similar data for 
invasion assays. 
 
Fig 3. GLP-2 enhances the increase in intestinal epithelial cell proliferation in response to 
myofibroblast conditioned media. A, Representative images of EdU (red) labelled HT29, 
SW480 and LoVo cells (nuclei stained blue with DAPI). B, GLP-2 has no direct effect on 
proliferation of SW480 or LoVo cells and a small effect on HT29 cells. C, Conditioned media 
from myofibroblasts stimulates EdU incorporation in SW480, HT29 and LoVo cells: the 
responses are enhanced by previous treatment of myofibroblasts with GLP-2 and are 
blocked by the IGF receptor inhibitor AG1024. D, in CeCo assays myofibroblast CM 
stimulates growth of SW480, HT29 and LoVo cells and the effect is enhanced by prior 
treatment of myofibroblasts with GLP-2; GLP-2 alone has no effect. 
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Fig 4.   GLP-2 enhances the increase in intestinal epithelial cell migration and invasion in 
response to myofibroblast conditioned media. A, GLP-2 alone (10nM) has no effect on 
migration (left) or invasion (right) of SW480, HT29 or LoVo cells in Boyden chamber 
chemotaxis assays. B, Conditioned media (CM) from myofibroblasts stimulates migration of 
SW480, HT29 and LoVo cells: the responses are enhanced by previous treatment of 
myofibroblasts with 10nM GLP-2 (GLP-2 CM) and are blocked by the IGF receptor inhibitor 
AG1024. C, similar results for invasion assays. Horizontal bars, p<0.05, ANOVA.  
 
Fig 5. Mutual stimulation of migration by epithelial cells and myofibroblasts in co-cultures 
treated with GLP-2. A, Representative images of Ibidi chambers with CAMs on one side and 
either SW480, HT29 or LoVo cells on the other side; on the left is a schematic illustrating the 
experimental design; thereafter are images taken at 0, 6, 24, 32 and 42 h. At each time point 
epithelial cells are shown on the left and CAMs on the right; the box indicates the area in 
which cells were quantified. B, time course of responses measured as numbers of cells in 
the defined area migrating towards the opposite side in either control co-cultures, or treated 
with GLP-1. The data are shown for co-cultures of SW480 and CAMs (left), HT29 and CAMs 
(centre), and LoVo cells and CAMs (right). In each case the data for epithelial cells are in the 
upper panel and CAMs from the corresponding co-culture in the lower panel. Horizontal 
bars, p<0.05, ANOVA.  
 
Fig 6. Western blot showing IGFBP-4, -5 and –7, and MMP-1, -2, -3 and -10 after GLP-2 
treatment of myofibroblasts. A, IGFBP-4, -5 and –7 in media of CAMs treated with GLP-2 
(10nM, 24h) with or without the MMP-inhibitor GM6001 (10 M). B, similar data including 
GAPDH for corresponding cell extracts. C, MMP-1, -2, -3 and -10 in media of CAMs treated 
with GLP-2. D, MMP-1 and GAPDH in the corresponding cell extracts.  
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
Shawe-Taylor, page 1 
 
Glucagon-like petide-2 acts on colon cancer myofibroblasts to stimulate proliferation, 1 
migration and invasion of both myofibroblasts and cancer cells via the IGF pathway 2 
 3 
Marianne Shawe-Taylor, J. Dinesh Kumar, Whitney Holden, Steven Dodd, Akos Varga, 4 
Olivier Giger, Andrea Varro, Graham J. Dockray 5 
 6 
Department of Cellular and Molecular Physiology, Institute of Translational Medicine, 7 
University of Liverpool, Liverpool UK. 8 
 9 
Short title: GLP-2 actions on colonic myofibroblasts 10 
 11 
Key words: GLP-2, IGF, IGFBP, myofibroblast migration, proliferation. 12 
 13 
 14 
Address correspondence to: 15 
Graham Dockray 16 
Department of Cell and Molecular Physiology 17 
Institute of Translational Medicine 18 
University of Liverpool 19 
Crown St 20 
Liverpool 21 
L69 3BX 22 
UK 23 
 24 
Email: g.j.dockray@liverpool.ac.uk  25 
Tel: (00)(44)151 794 5324 26 
   27 
28 
*Manuscript
Click here to download Manuscript: GLP2~02~20~17~CLEAN~REVISED.doc Click here to view linked References
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
Shawe-Taylor, page 2 
 
  29 
Abbreviations: ATMs, adjacent tissue myofibroblasts; CAMs, cancer associated 30 
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Highlights 40 
- GLP-2  stimulates proliferation and invasion of primary colonic cancer-derived 41 
myofibroblasts to a greater extent than those from adjacent tissue; GLP-2 42 
conditioned medium from myofibroblasts stimulated proliferation, migration and 43 
invasion of intestinal epithelial cells.  44 
- An inhibitor of IGF receptor signalling blocks the effect of GLP-2 on colonic 45 
myofibroblasts. 46 
- GLP-2 increases IGF-1 and -2 transcript abundance in myofibroblasts and stimulates 47 
degradation of IGF binding proteins in myofibroblasts medium, compatible with 48 
increased bioavailability of IGF.  49 
- GLP-2 may influence the cancer microenvironment via actions on stromal cells such 50 
as myofibroblasts.  51 
 52 
53 
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Abstract  54 
Glucagon-like peptide (GLP)-2 stimulates intestinal epithelial proliferation by acting, in part, 55 
via IGF release from sub-epithelial myofibroblasts. The response of myofibroblasts to GLP-2 56 
remains incompletely understood. We studied the action of GLP-2 on myofibroblasts from 57 
colon cancer and adjacent tissue, and the effects of conditioned medium from these cells on 58 
epithelial cell proliferation, migration and invasion. GLP-2 stimulated proliferation, migration 59 
and invasion of myofibroblasts and the proliferative and invasive responses of cancer-60 
associated myofibroblasts were greater than those of myofibroblasts from adjacent tissue. 61 
The responses were inhibited by an IGF receptor inhibitor, AG1024. Conditioned medium 62 
from GLP-2 treated myofibroblasts increased proliferation, migration and invasion of SW480, 63 
HT29, LoVo epithelial cells and these responses were inhibited by AG1024; GLP-2 alone 64 
had no effect on these cells.  In addition, when myofibroblasts and epithelial cells were co-65 
cultured in Ibidi chambers there was mutual stimulation of migration in response to GLP-2. 66 
The latter increased both IGF-1 and IGF-2 transcript abundance in myofibroblasts. 67 
Moreover, a number of IGF binding proteins (IGFBP-4, -5, -7) were identified in 68 
myofibroblast medium; in the presence of GLP-2 there was increased abundance of the 69 
cleavage products of IGBBP-4 and IGFBP-5 suggesting activation of a degradation 70 
mechanism that might increase IGF bioavailability. The data suggest that GLP-2 stimulates 71 
cancer myofibroblast proliferation, migration and invasion; GLP-2 acts indirectly on epithelial 72 
cells partly via increased IGF expression in myofibroblasts and partly, perhaps, by increased 73 
bioavailability through degradation of IGFBPs.    74 
75 
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Introduction 76 
Mucosal morphology throughout the gastrointestinal tract is determined by interactions 77 
between epithelial cells and underlying stromal cells which release a variety of growth 78 
factors [34]. These interactions are also a feature of tumour growth where it is now clear that 79 
stromal cells provide a supportive and stimulatory niche for cancer cells [16, 35]. A key 80 
stromal cell type is the myofibroblast which normally lies in close proximity to the basal 81 
membrane of epithelial cells while in cancer these cells are an important component of the 82 
stroma that may constitute a high proportion of tumour volume. There is now clear evidence 83 
that cancer-associated myofibroblasts (CAMs, often considered to be a subset of cancer-84 
associated fibroblasts) are functionally distinct from myofibroblasts recovered from tissue 85 
adjacent to the tumour (ATMs), and from normal tissue [18, 19].  86 
 87 
A range of hormonal signals from epithelial enteroendocrine cells (EECs) influence growth of 88 
the gastrointestinal tract, including gastrin, cholecystokinin and glucagon-like peptide (GLP)-89 
2. The latter is generated from the glucagon precursor by post-translational cleavage; there 90 
are different patterns of processing in pancreatic alpha-cells and L-cells of the ileum and 91 
colon. In particular, the main products in L-cells are GLP-2, GLP-1 (which is an insulin 92 
secretagogue) and oxyntomodulin (which is a C-terminally extended variant of glucagon). A 93 
link between glucagon gene expression and intestinal hypertrophy has been known for 94 
several decades, and it is now recognised that GLP-2 is a crucial mediator [10]. Interestingly, 95 
GLP-2 receptors are not expressed on intestinal epithelial cells, with the possible exception 96 
of some EECs, and as a consequence GLP-2 does not have direct effects on intestinal 97 
epithelial cell proliferation. Instead there is evidence that GLP-2 acts indirectly via sub-98 
epithelial cells notably myofibroblasts and neurons [2, 5, 11, 32]. Thus, the evidence 99 
suggests that GLP-2 releases growth factors such as IGF, KGF, VEGF-A and EGF-family 100 
members which in turn act on epithelial cells to stimulate cell proliferation [7, 13, 32, 40]. 101 
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Gene array data indicate that a wide variety of gastrointestinal myofibroblasts produce both 102 
IGF-1 and IGF-2 as well as a number of IGF binding proteins (IGFBPs) including -3, -4, -5, -103 
6 and -7 [4]. The IGFBPs act to sequester extracellular IGF which can be liberated by IGFBP 104 
cleavage, for example by matrix metalloproteinase (MMP)-7 produced by epithelial cells [17]. 105 
In the upper gastrointestinal tract, the IGFs act on both epithelial cells and the myofibroblasts 106 
themselves to stimulate proliferation as well as migration and invasion. The response of 107 
intestinal myofibroblasts to GLP-2 remains relatively unexplored. While there have been 108 
studies using a CCD18 myofibroblast cell line, which is derived from normal intestine of a 109 
human infant, the possible effects of GLP-2 on cancer myofibroblasts are unclear. The 110 
question is of interest in the context of colon cancer, because GLP-2 stimulates normal 111 
colonic, as well as small intestinal, growth [30] and reduces injury in a mouse model of colitis 112 
[12]; moreover in some mouse models of colon cancer there is evidence that GLP-2 may 113 
exert growth-promoting effects [38]. A recent review hypothesized that GLP-2 might act via 114 
cancer associated fibroblasts [23]. However, direct studies of the action of GLP-2 on stromal 115 
cells from colorectal carcinoma have been neglected. In the present study we have 116 
examined the hypothesis that GLP-2 acts on myofibroblasts from colon cancer and adjacent 117 
tissue to influence colon cancer cells lines, and have examined the role of IGF in mediating 118 
these effects.  119 
 120 
121 
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Materials and Methods 122 
 123 
Cells. Colon cancer cells (HT29, Lovo, SW480) and CCD18 colonic myofibroblasts were 124 
obtained from American type culture collection (VA, US). Myofibroblasts were generated 125 
from a colon tumour (CAMs) and adjacent tissue (ATMs) of an 85 year old female patient 126 
(T3N2M0; post-operative survival 2 months) as previously described [19, 24]; these cells 127 
were positive by immunohistochemistry for -smooth muscle actin and vimentin, and were 128 
negative for desmin and cytokeratin. Cancer cells and myofibroblasts were cultured as 129 
previously described [19].  130 
 131 
Conditioned media. Myofibroblasts (1.5 x 106 cells) were plated in T-75 falcon flasks and 132 
maintained at 37oC in a 5% v/v CO2 atmosphere for 24h in full media (FM). Cultures were 133 
then washed 3 times with sterile PBS and incubated in 15ml serum free (SF) media with or 134 
without GLP-2 (AnaSpec, Freemont, CA, USA) for 24h. Conditioned medium (CM) was 135 
collected, centrifuged (7 min, 800 x g, 4oC) and aliquots were stored at -80oC until further 136 
use. 137 
 138 
EdU incorporation and Cell Counting Kit-8 assays  139 
For EdU incorporation assays, colonic myofibroblasts and colon cancer cells (2.5x104 per 140 
well) were seeded and incubated overnight in FM followed by serum starvation for 48 h. 141 
Cells then were treated with GLP-2 or CM as appropriate for 24h. Proliferation was assessed 142 
by incorporation of 5-ethynyl-2’-deoxyuridine (EdU, 10 µM, 16h) and processing of samples 143 
using Click-iT (Invitrogen, Paisley, UK) and Alexa 568-azide. EdU positive cells were 144 
visualised on a Zeiss AxioCam HRM fluorescence microscope (Carl Zeiss, Welwyn Garden 145 
City, UK) on a 40x objective lens counting the total number of cell nuclei in 10 different fields 146 
using DAPI (Vector Laboratories, Peterborough, UK) (blue) and EdU positive nuclei.  147 
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Cell Counting Kit-8 assays (Dojindo Laboratories, Munich, Germany; the manufacturers use 148 
the abbreviation “CCK8” to describe these kits, but to avoid confusion with cholecystokinin 149 
octapeptide which shares the same abbreviation, we use the alternative contraction “CeCo” 150 
assays here) were performed on colonic myofibroblasts and cancer cells (8x103 per well) in 151 
96 well plates incubated overnight in FM followed by incubation with GLP-2 or CM medium 152 
in phenol red free SF medium for 72h. On the last day 10µl CeCo reagent was added to the 153 
wells and incubated for 2-4h as optimised for each cell type. Readings were taken at 450nm 154 
using a GenioPlus plate reader (Tecan, Zurich, Switzerland). 155 
 156 
Cell migration and invasion assays. Transwell migration and invasion assays were 157 
performed using BD inserts (Corning, New York, USA) as previous described (2.5 x 104 cells 158 
per insert) [39]. GLP-2 or CM were added in the lower well together with AG1024 159 
(Calbiochem, Darmstadt, Germany) as appropriate. Ibidi chamber (Ibidi GmbH, Martinsried, 160 
Germany) migration assays were performed in 24 well plates. Ibidi culture inserts were 161 
placed at the bottom of the wells followed by seeding of 105 cancer cells and 5x104 162 
myofibroblasts on separate sides of the insert. After 24h the insert was removed, leaving a 163 
500µm wound; cells were then treated with GLP-2 up to 42h and images taken with a 164 
Hamamatsu Camera (Hamamatsu Photonics, Hamamatsu City, Japan) at 0, 6, 24, 32, 42h 165 
using a Leica DMIRE2 microscope on a heated stage, humidified chamber (Solent Scientific, 166 
Portsmouth, UK); cells in the wound were counted in 5-8 fields per insert. 167 
 168 
qPCR. RNA was extracted in 1.25 ml Tri-Reagent (Sigma, Dorset, UK) according to the 169 
manufacturer’s instructions from control and GLP-2 treated colonic myofibroblasts. RNA 170 
pellets were re-suspended in 50 l of nuclease free water and 4 µg of RNA reverse 171 
transcribed with avian myeloblastosis virus reverse transcriptase and oligo-dT primers 172 
(Promega). Real time PCR was carried out using an ABI7500 platform (Applied Biosystems, 173 
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Warrington, UK) using TaqMan primer/probe sets (human IGF-1, IGF-2, GAPDH), Precision 174 
Plus 2x real time PCR master mix (Primer Design, Southampton, UK) and 5’-FAM, 3’-175 
TAMRA double dye probes (Eurogentec, Southampton, UK). All values were standardized to 176 
GAPDH. Assays included a no template control (NTC), and a standard curve as previously 177 
described [28]. Primers and probes were designed using Primer Express v3.0 (Applied 178 
Biosystems) and were purchased from Eurogentec (Seraing, Belgium). Probes for detection 179 
of human GAPDH, IGF-1 and IGF-2 cDNA were intron-spanning and were: GAPDH: 5’-GCT 180 
CCT CCT GTT CGA CAG TCA-3’(forward), 5’-ACC TTC CCC ATG GTG TCT GA-3’ 181 
(reverse),  5’-CGT CGC CAG CCG AGC CAC A-3’ (probe); IGF-1: 5’-TGT ATT GCG CAC 182 
CCC TCA A-3’ (forward), 5’-CT CCC TCT ACT TGC GTT CTT CA-3’ (reverse), 5’-ACA TGC 183 
CCA AGA CCC AGA AGG AAG TAC A-3’ (probe); IGF-2, 5’-CCG TGC TTC CGG ACA ACT 184 
T-3’ (forward), 5’-GGA CTG CTT CCA GGT GTC ATA TT-3’ (reverse), 5’-CCC AGA TAC 185 
CCC GTG GGC AAG TTC-3’ (probe). 186 
 187 
Western blotting. Cell extracts were prepared in RIPA buffer and media samples were 188 
concentrated with StrataClean resins (Agilent Technologies Ltd, Santa Clara, CA, USA) and 189 
processed for Western blotting as previously described  [28] using antibodies to IGFBP-3, 4, 190 
5 and -7, MMP-1, -2, -3 and -10 (R&D Systems) and GAPDH (Biodesign, Maine, USA). 191 
 192 
Statistics. Results were calculated as mean ± standard error of means (SEM). Student t-193 
test and ANOVA were performed on the data as appropriate with significance at p<0.05 194 
using Systat Software Inc. (London, UK) unless otherwise stated.  195 
196 
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Results 197 
GLP-2 stimulates myofibroblast proliferation. In initial studies we showed that GLP-2 198 
produced a dose-related increase in EdU incorporation into CCD18 myofibroblasts (Fig 199 
1A,B). We then studied EdU incorporation by colonic CAMs and ATMs. As previously 200 
reported for gastric CAMs [19], basal EdU incorporation was greater in the colonic CAMs 201 
compared with the corresponding ATMs. In the presence of GLP-2 there was stimulation of 202 
EdU incorporation into both CAMs and ATMs and the response in the former was greater 203 
than the latter (Fig 1C). In a CeCo assay of cell growth, GLP-2 also stimulated colonic CAM 204 
growth and to a lesser extent that of ATMs (Fig 1D). 205 
 206 
GLP-2 stimulates myofibroblast migration and invasion. We then examined the actions 207 
of GLP-2 on CAM and ATM migration and invasion using Boyden chambers (Fig 2A,B). In 208 
both cell types, GLP-2 at a concentration that stimulated proliferation also stimulated 209 
migration and these responses were similar in CAMs and ATMs; moreover in both cases 210 
they were abolished by AG1024 which selectively inhibits IGF-1 receptor tyrosine kinase 211 
activity at the concentrations used [33]. Similarly, there was IGF-dependent stimulation of 212 
CAM invasion and in this case the response was significantly greater than that of ATMs. 213 
 214 
Myofibroblast conditioned medium stimulates epithelial cell proliferation. Consistent 215 
with a previous report that epithelial cells lines lack the capacity to respond to GLP-2 [25], 216 
there was no change in EdU incorporation (Fig 3A) by two of the epithelial cell lines used in 217 
the present study (SW480 and LoVo) in response to GLP-2 applied directly to the cells while 218 
there was a small effect on HT29 cells (Fig 3B). However, there was a small increase in EdU 219 
incorporation in response to CAM CM in SW480 cells that was enhanced by pre-treatment of 220 
myofibroblasts with GLP-2 and there were greater increases in EdU incorporation by HT29 221 
and LoVo cells in response to CAM CM, and in both cases there were small further 222 
increases using CM from GLP-2-treated myofibroblasts. In all three intestinal cell lines, the 223 
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responses to control CM and to GLP-2 CM were suppressed by AG1024 (Fig 3C). In CeCo 224 
assays of cell growth, there were robust responses by all three intestinal epithelial lines to 225 
control myofibroblast CM and small but significantly increases in response to GLP-2 226 
pretreatment of myofibroblasts (Fig 3D).  227 
 228 
Myofibroblast conditioned medium stimulates epithelial cell migration and invasion. 229 
When GLP-2 was applied directly to epithelial cells (SW480, HT29, LoVo) there was no 230 
effect on migration or invasion in Boyden chambers (Fig 4A). However, there was strong 231 
stimulation of migration of all three cell lines in response to control CAM CM and there were 232 
small but significant further increases in response to CM from GLP-2 treated myofibroblasts 233 
(Fig 4B). In each case the response was inhibited by AG1024. There were relatively modest 234 
increases in invasion of HT29 and LoVo cells in response to control myofibroblast CM but 235 
the response was strongly enhanced by GLP-2-treated CM; all responses were inhibited by 236 
AG1024 (Fig 4C). 237 
 238 
GLP-2 stimulates migration in co-cultures of epithelial cells and myofibroblasts. In 239 
view of the potential for cross-talk between epithelial cells and myofibroblasts we then asked 240 
whether the response to GLP-2 was preserved when these cells were co-cultured. For this 241 
purpose we used Ibidi chambers with myofibroblasts in one chamber and epithelial cells in 242 
the other so that subsequent removal of the insert yielded cultures of the two cells separated 243 
by 500 m (Fig 5A). Over a period of 42 h after removing the insert there was progressive 244 
migration of both cell types toward each other (Fig 5A). The numbers of migrating epithelial 245 
cells were roughly 10 times higher than those of myofibroblasts. Nevertheless at each time 246 
point examined from 6 – 42 h the presence of GLP-2 increased the migration of each of the 247 
epithelial cell lines and of the co-cultured CAMs (Fig 5B). 248 
 249 
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GLP-2 increases IGF-1 and IGF-2 transcript abundance. In view of the evidence that 250 
GLP-2 might act via IGF we first examined microarray data from myofibroblasts which 251 
indicated that both IGF-1 and IGF-2 were expressed in colonic CAMs and ATMs; the relative 252 
abundance of IGF-1 in colonic myofibroblasts was higher compared to IGF-2, while in gastric 253 
myofibroblasts IGF-2 was dominant [4]. We then used qPCR for both IGF-1 and IGF-2 to 254 
assess responses to GLP-2. At a concentration of GLP-2 (10 nM) that increased 255 
myofibroblast migration and proliferation, there was 1.8 ± 0.2 fold higher IGF-1 transcript 256 
abundance and 1.5 ± 0.2 fold higher IGF-2 transcript abundance.  257 
 258 
GLP-2 promotes IGFBP degradation in myofibroblasts medium. Since there is evidence 259 
that GLP-2 might act via IGFBP-4 [1] we examined by Western blot the profile of IGFBP-4 260 
and also of IGFBP-3, -5 and -7 in CAMs treated with GLP-2. In control media there were 261 
clear bands corresponding to intact IGFBP-4, -5 and -7 (Fig 6A), while IGFBP-3 was 262 
undetectable (not shown). There were also minor bands corresponding to degradation 263 
products of IGFBP4 (15 kD) and  IGFBP-5 (10-15 kD). In the presence of GLP-2 the bands 264 
corresponding to intact IGFBP-4, and -5 were maintained but there was increased 265 
abundance of the degradation products. In the presence of an inhibitor of MMP activity 266 
(GM6001, 10 M) the action of GLP-2 in promoting degradation of IGFBP4 and -5 was 267 
inhibited (Fig 6A). There was also an increase in IGFBP-4 and -5 in cell extracts in response 268 
to GLP-2 compatible with increased expression (Fig 6B). Multiple proMMPs are secreted by 269 
myofibroblasts (MMP-1, -2, -3 and -10) [18]. Of these, MMP-1 was increased in abundance 270 
in GLP-2 treated cells and media (Fig 6C,D) although there was little or no change in MMP-271 
2, -3 and -10. 272 
 273 
274 
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Discussion 275 
The present study provides evidence that GLP-2 acts on cancer-derived myofibroblasts to 276 
stimulate their proliferation, migration and invasion. These effects are blocked by an inhibitor 277 
of IGF1 receptor tyrosine kinase and since there is an increase in IGF-1 and -2 transcript 278 
abundance as well as increased degradation of IGFBP-4 and -5, the data support the idea 279 
that the actions of GLP-2 on myofibroblasts are at least partly mediated by IGF. Consistent 280 
with previous findings, GLP-2 had little or no effect on three intestinal epithelial cell lines, but 281 
conditioned medium from CAMs stimulated proliferation, migration and invasion of these 282 
cells, and to varying degrees GLP-2 treatment of myofibroblasts enhanced the responses in 283 
an IGF-receptor dependent mechanism. The data add to previous work in this area by 284 
indicating (a) that GLP-2 might regulate myofibroblast numbers and motility, and (b) that 285 
myofibroblasts in cancer are putative targets for GLP-2. In view of the importance of 286 
myofibroblasts in determining the tumour microenvironment the data raise the prospect that 287 
GLP-2 might influence cancer progression.  288 
 289 
The importance of myofibroblasts as targets for the trophic action of GLP-2 in the intestine 290 
has been clear for some time [7, 32]. Previous work has made use of CCD18 myofibroblasts 291 
that are derived from normal infant intestine [7], mixed intestinal cell cultures [13] and 292 
intestinal sub-epithelial fibroblasts [29]. The present findings extend these studies to include 293 
myofibroblasts derived from colon cancer and adjacent tissue. For the most part previous 294 
studies have focussed on the mechanisms by which myofibroblasts influence epithelial cell 295 
growth. While the growth factor responses of the myofibroblasts themselves have received 296 
attention, less has been given to other aspects of myofibroblasts biology. The observation 297 
that GLP-2 increases myofibroblast cell number, and very likely cell position (via actions on 298 
migration/invasion), suggests a more dynamic system than previously supposed.  299 
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It is recognised that cancer-derived fibroblasts and myofibroblasts differ from their 301 
counterparts in normal tissue [9, 19, 31]. The different properties of CAMs may, at least to 302 
some extent, reflect epigenetic changes [22]. The differences are important given the 303 
emerging evidence that stromal cells in general [16], and myofibroblasts in particular, 304 
stimulate cancer progression [8]. Previous work has shown that in both gastric and 305 
oesophageal cancer, CAMs exhibit increased proliferation, migration and invasion compared 306 
with ATMs [19, 27]. The present study has shown that colonic CAMs similarly exhibit a more 307 
aggressive phenotype than colonic ATMs i.e. increased basal and stimulated proliferation 308 
and invasion in response to GLP-2. The fact that these cells retain the ability to respond to 309 
GLP-2 provides a mechanism by which GLP-2 might influence cancer progression [23]. The 310 
therapeutic value of GLP-2 in treatment of short bowel syndrome is now widely appreciated, 311 
but it would be as well to keep in mind that in some circumstances GLP-2 might have 312 
deleterious effects in influencing cellular microenvironments. A particularly clear example is 313 
provided by gastrointestinal stromal tumours that have been reported to express GLP-2R 314 
[26]; the possibility that GLP-2 may also act on colon cancers via their stromal component 315 
should now be considered.  316 
 317 
A number of growth factors have been proposed to mediate the actions of GLP-2 on 318 
myofibroblasts, including IGF [29], VEGF-A [7], KGF [32] and EGF-family members [3, 40]. It 319 
is important to be clear that these need not be mutually exclusive. Our data suggest that 320 
colonic CAMs stimulate epithelial cell growth, migration and invasion by an IGF-receptor 321 
dependent mechanism [37] that is enhanced to varying degrees by treatment of 322 
myofibroblasts with GLP-2. The increase in epithelial proliferation was modest, the migratory 323 
response was stronger and the invasive responses in two cells lines were very strong. High 324 
constitutive expression of IGF has already been reported [29] and would account for the 325 
present findings on intestinal epithelial cell proliferation and migration. In the case of the 326 
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strong invasion response of these cells we suggest that increased bioavailability of IGF as 327 
well as increased MMP-activity [18] might interact to enhance the response.  328 
 329 
There was increased transcript abundance of IGF-1 and IGF-2 in response to GLP-2 which 330 
would provide one mechanism to account for the biological responses of both epithelial cells 331 
and myofibroblasts. However, our data suggest that there are also likely to be other 332 
mechanisms. Secreted IGF is sequestered by IGFBPs. In gastrointestinal myofibroblasts the 333 
main IGFBPs include IGFBP-4, -5 and -7. Cleavage of IGFBP-5 by MMP-7 released by 334 
epithelial cells has previously been shown to increase the bioavailability of IGF-2 which may 335 
stimulate both epithelial and stromal cells [17]. In addition to regulating IGF bioavailability, 336 
some IGFBPs or their fragments, may exert independent biological activities [14, 20]. 337 
Recently, a role for IGFBP-4 in mediating the effects of GLP-2 was indicated by the 338 
observation that in mice null for IGFBP-4 the effect of GLP-2 was inhibited [1]. The precise 339 
cellular mechanisms remain uncertain, but it is interesting that in our studies GLP-2 340 
treatment of myofibroblasts increased the abundance of IGFBP-4 degradation products seen 341 
in western blot; there was a similar effect on IGFBP-5 but not IGFBP-7.  Moreover, there 342 
was an increase in cellular abundance of IGFBP-4 and -5 compatible with stimulation of 343 
expression by GLP-2 as previously reported [1]. The degradation of IGFBP-4 in other 344 
systems is attributable to PAPP-A which is a member of the pappalysin group of metzincin 345 
metalloproteinase [6]. The GLP-2 stimulated degradation of IGFBP-4 and -5 was blocked by 346 
a broad spectrum inhibitor of MMP activity, GM6001, which is reported to have little effect on 347 
pappalysins [15]. We found GLP-2 increased the abundance in media and cell extracts of 348 
proMMP-1 (although not proMMP-2, -3 and -10). We suggest therefore, that GLP-2 349 
increases the expression in myofibroblasts of IGFBP-4 and -5, and proMMP-1. Further work 350 
is now needed to determine the biological significance of the degradation products of 351 
IGFBP-4 and -5, particularly with respect to IGF binding and any potential biological activities 352 
independent of IGF.  353 
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The maintenance of tissue architecture is presumed to involve two-way interactions in vivo 354 
between myofibroblasts and epithelial cells. We attempted to design a simple in vitro model 355 
to establish whether the actions of GLP-2 on myofibroblasts, and those of myofibroblasts on 356 
epithelial cells, were preserved when the two cell types were in co-culture. The data 357 
obtained using Ibidi chambers indicate that the migratory responses observed when the two 358 
cells were cultured separately were preserved in co-cultures. Interestingly, though, the 359 
magnitude of the migratory responses by epithelial cells was considerably greater than that 360 
of myofibroblasts. Nevertheless the data allow us to conclude that any feedback mechanism 361 
from intestinal cells that might exist to limit the myofibroblast response to GLP-2 is relatively 362 
modest. 363 
 364 
Alongside an appreciation of the therapeutic benefits of GLP-2, there has also been an 365 
appreciation, based on data from animal models, that GLP-2 might have growth promoting 366 
effects with deleterious consequences in cancer [36]. Thus in two mouse models of 367 
carcinogen-induced colon cancer (dimethylhydrazine, azoxymethane) administration of GLP-368 
2 increased tumour size [21, 38], although in other models eg APCmin-/- mice, it had no effect 369 
[25]. Whether or not GLP-2 aggravates human colon cancer progression needs to be kept 370 
under review. The case for further studies of GLP-2 and human colon cancer is supported by 371 
the present data which raise the prospect that GLP-2 acts on human colon cancer-derived 372 
myofibroblasts to trigger pathways influencing myofibroblast number and motility and, 373 
indirectly, cancer cell function. It is worth stressing, that since the present data indicate that 374 
GLP-2 targets the IGF system in colonic myofibroblasts this system would presumably be 375 
susceptible to novel therapeutic strategies targeted at IGF-responsive cells in colon cancer 376 
[41].  377 
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Legends 497 
Fig 1. GLP-2 stimulates myofibroblast proliferation. A, Representative image of EdU labelled 498 
myofibroblast (filled arrow; unlabelled cells, open arrows). B, dose-response relationship for 499 
GLP-2 stimulation of EdU incorporation by CCD-18 cells (n = 4). C, GLP-2 (10 nM) 500 
stimulates EdU incorporation into both cancer-derived myofibroblasts (CAM, n = 6) and 501 
adjacent tissue myofibroblasts (ATM, n = 3). D, GLP-2 also increases cell growth measured 502 
by CeCo assay (n = 4). Horizontal arrows * p<0.05, ** p<0.01,  *** p<0.001.  503 
 504 
Fig 2. Stimulation of myofibroblast migration by GLP-2. A, GLP-2 (10nM) increases migration 505 
of both CAMs and ATMs in Boyden chamber chemotaxis assays and the response is 506 
reversed by an inhibitor of IGF1 receptor tyrosine kinase (AG1024, 20μM)(n = 3 – 6). B, 507 
similar data for invasion assays (n = 3). See Legend to Fig 1 for further details. 508 
 509 
Fig 3. GLP-2 enhances the increase in intestinal epithelial cell proliferation in response to 510 
myofibroblast conditioned media. A, Representative images of EdU (red) labelled HT29, 511 
SW480 and LoVo cells (nuclei stained blue with DAPI). B, GLP-2 (10 nM) has no direct 512 
effect on proliferation of SW480 or LoVo cells and a small effect on HT29 cells (n = 3). C, 513 
Conditioned media from myofibroblasts stimulates EdU incorporation in SW480, HT29 and 514 
LoVo cells: the responses are enhanced by previous treatment of myofibroblasts with GLP-2 515 
(10 nM) and are blocked by the IGF receptor inhibitor AG1024 (20 M)(n = 3 – 6). D, in 516 
CeCo assays myofibroblast CM stimulates growth of SW480, HT29 and LoVo cells and the 517 
effect is enhanced by prior treatment of myofibroblasts with GLP-2 (10 nM); GLP-2 alone 518 
has no effect (n = 3 – 4). See Legend to Fig 1 for further details. 519 
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 521 
Fig 4.   GLP-2 enhances the increase in intestinal epithelial cell migration and invasion in 522 
response to myofibroblast conditioned media. A, GLP-2 alone (10nM) has no effect on 523 
migration (left) or invasion (right) of SW480, HT29 or LoVo cells in Boyden chamber 524 
chemotaxis assays (n = 3). B, Conditioned media (CM) from myofibroblasts stimulates 525 
migration of SW480, HT29 and LoVo cells: the responses are enhanced by previous 526 
treatment of myofibroblasts with 10nM GLP-2 (GLP-2 CM) and are blocked by the IGF 527 
receptor inhibitor AG1024 (20 M)(n = 3 – 6). C, similar results for invasion assays (n = 3). 528 
See Legend to Fig 1 for further details. 529 
 530 
 531 
Fig 5. Mutual stimulation of migration by epithelial cells and myofibroblasts in co-cultures 532 
treated with GLP-2. A, Representative images of Ibidi chambers with CAMs on one side and 533 
either SW480, HT29 or LoVo cells on the other side; on the left is a schematic illustrating the 534 
experimental design; thereafter are images taken at 0, 6, 24, 32 and 42 h. At each time point 535 
epithelial cells are shown on the left and CAMs on the right; the box indicates the area in 536 
which cells were quantified. B, time course of responses measured as numbers of cells in 537 
the defined area migrating towards the opposite side in either control co-cultures, or treated 538 
with GLP-2 (10 nM). The data are shown for co-cultures of SW480 and CAMs (left), HT29 539 
and CAMs (centre), and LoVo cells and CAMs (right). In each case the data for epithelial 540 
cells are in the upper panel and CAMs from the corresponding co-culture in the lower panel 541 
(n = 3). See Legend to Fig 1 for further details. 542 
 543 
Fig 6. Western blots showing IGFBP-4, -5 and –7, and MMP-1, -2, -3 and -10 after GLP-2 544 
treatment of myofibroblasts. A, IGFBP-4, -5 and –7 in media of CAMs treated with GLP-2 545 
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(10nM, 24h) with or without the MMP-inhibitor GM6001 (10 M). B, similar data including 546 
GAPDH for corresponding cell extracts. C, MMP-1, -2, -3 and -10 in media of CAMs treated 547 
with GLP-2. D, MMP-1 and GAPDH in the corresponding cell extracts. Representative 548 
images from 4 independent experiments.   549 
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Highlights 
- GLP-2  stimulates proliferation and invasion of primary colonic cancer-derived 
myofibroblasts to a greater extent than those from adjacent tissue; GLP-2 
conditioned medium from myofibroblasts stimulated proliferation, migration and 
invasion of intestinal epithelial cells.  
- An inhibitor of IGF receptor signalling blocks the effect of GLP-2 on colonic 
myofibroblasts. 
- GLP-2 increases IGF-1 and -2 transcript abundance in myofibroblasts and stimulates 
degradation of IGF binding proteins in myofibroblasts medium, compatible with 
increased bioavailability of IGF.  
- GLP-2 may influence the cancer microenvironment via actions on stromal cells such 
as myofibroblasts.  
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Abstract  
Glucagon-like peptide (GLP)-2 stimulates intestinal epithelial proliferation by acting, in part, 
via IGF release from sub-epithelial myofibroblasts. The response of myofibroblasts to GLP-2 
remains incompletely understood. We studied the action of GLP-2 on myofibroblasts from 
colon cancer and adjacent tissue, and the effects of conditioned medium from these cells on 
epithelial cell proliferation, migration and invasion. GLP-2 stimulated proliferation, migration 
and invasion of myofibroblasts and the proliferative and invasive responses of cancer-
associated myofibroblasts were greater than those of myofibroblasts from adjacent tissue. 
The responses were inhibited by an IGF receptor inhibitor, AG1024. Conditioned medium 
from GLP-2 treated myofibroblasts increased proliferation, migration and invasion of SW480, 
HT29, LoVo epithelial cells and these responses were inhibited by AG1024; GLP-2 alone 
had no effect on these cells.  In addition, when myofibroblasts and epithelial cells were co-
cultured in Ibidi chambers there was mutual stimulation of migration in response to GLP-2. 
The latter increased both IGF-1 and IGF-2 transcript abundance in myofibroblasts. 
Moreover, a number of IGF binding proteins (IGFBP-4, -5, -7) were identified in 
myofibroblast medium; in the presence of GLP-2 there was increased abundance of the 
cleavage products of IGBBP-4 and IGFBP-5 suggesting activation of a degradation 
mechanism that might increase IGF bioavailability. The data suggest that GLP-2 stimulates 
cancer myofibroblast proliferation, migration and invasion; GLP-2 acts indirectly on epithelial 
cells partly via increased IGF expression in myofibroblasts and partly, perhaps, by increased 
bioavailability through degradation of IGFBPs.    
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Introduction 
Mucosal morphology throughout the gastrointestinal tract is determined by interactions 
between epithelial cells and underlying stromal cells which release a variety of growth 
factors [34]. These interactions are also a feature of tumour growth where it is now clear that 
stromal cells provide a supportive and stimulatory niche for cancer cells [16, 35]. A key 
stromal cell type is the myofibroblast which normally lies in close proximity to the basal 
membrane of epithelial cells while in cancer these cells are an important component of the 
stroma that may constitute a high proportion of tumour volume. There is now clear evidence 
that cancer-associated myofibroblasts (CAMs, often considered to be a subset of cancer-
associated fibroblasts) are functionally distinct from myofibroblasts recovered from tissue 
adjacent to the tumour (ATMs), and from normal tissue [18, 19].  
 
A range of hormonal signals from epithelial enteroendocrine cells (EECs) influence growth of 
the gastrointestinal tract, including gastrin, cholecystokinin and glucagon-like peptide (GLP)-
2. The latter is generated from the glucagon precursor by post-translational cleavage; there 
are different patterns of processing in pancreatic alpha-cells and L-cells of the ileum and 
colon. In particular, the main products in L-cells are GLP-2, GLP-1 (which is an insulin 
secretagogue) and oxyntomodulin (which is a C-terminally extended variant of glucagon). A 
link between glucagon gene expression and intestinal hypertrophy has been known for 
several decades, and it is now recognised that GLP-2 is a crucial mediator [10]. Interestingly, 
GLP-2 receptors are not expressed on intestinal epithelial cells, with the possible exception 
of some EECs, and as a consequence GLP-2 does not have direct effects on intestinal 
epithelial cell proliferation. Instead there is evidence that GLP-2 acts indirectly via sub-
epithelial cells notably myofibroblasts and neurons [2, 5, 11, 32]. Thus, the evidence 
suggests that GLP-2 releases growth factors such as IGF, KGF, VEGF-A and EGF-family 
members which in turn act on epithelial cells to stimulate cell proliferation [7, 13, 32, 40]. 
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Gene array data indicate that a wide variety of gastrointestinal myofibroblasts produce both 
IGF-1 and IGF-2 as well as a number of IGF binding proteins (IGFBPs) including -3, -4, -5, -
6 and -7 [4]. The IGFBPs act to sequester extracellular IGF which can be liberated by IGFBP 
cleavage, for example by matrix metalloproteinase (MMP)-7 produced by epithelial cells [17]. 
In the upper gastrointestinal tract, the IGFs act on both epithelial cells and the myofibroblasts 
themselves to stimulate proliferation as well as migration and invasion. The response of 
intestinal myofibroblasts to GLP-2 remains relatively unexplored. While there have been 
studies using a CCD18 myofibroblast cell line, which is derived from normal intestine of a 
human infant, the possible effects of GLP-2 on cancer myofibroblasts are unclear. The 
question is of interest in the context of colon cancer, because GLP-2 stimulates normal 
colonic, as well as small intestinal, growth [30] and reduces injury in a mouse model of colitis 
[12]; moreover in some mouse models of colon cancer there is evidence that GLP-2 may 
exert growth-promoting effects [38]. A recent review hypothesized that GLP-2 might act via 
cancer associated fibroblasts [23]. However, direct studies of the action of GLP-2 on stromal 
cells from colorectal carcinoma have been neglected. In the present study we have 
examined the hypothesis that GLP-2 acts on myofibroblasts from colon cancer and adjacent 
tissue to influence colon cancer cells lines, and have examined the role of IGF in mediating 
these effects.  
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Materials and Methods 
 
Cells. Colon cancer cells (HT29, Lovo, SW480) and CCD18 colonic myofibroblasts were 
obtained from American type culture collection (VA, US). Myofibroblasts were generated 
from a colon tumour (CAMs) and adjacent tissue (ATMs) of an 85 year old female patient 
(T3N2M0; post-operative survival 2 months) as previously described [19, 24]; these cells 
were positive by immunohistochemistry for -smooth muscle actin and vimentin, and were 
negative for desmin and cytokeratin. Cancer cells and myofibroblasts were cultured as 
previously described [19].  
 
Conditioned media. Myofibroblasts (1.5 x 106 cells) were plated in T-75 falcon flasks and 
maintained at 37oC in a 5% v/v CO2 atmosphere for 24h in full media (FM). Cultures were 
then washed 3 times with sterile PBS and incubated in 15ml serum free (SF) media with or 
without GLP-2 (AnaSpec, Freemont, CA, USA) for 24h. Conditioned medium (CM) was 
collected, centrifuged (7 min, 800 x g, 4oC) and aliquots were stored at -80oC until further 
use. 
 
EdU incorporation and Cell Counting Kit-8 assays  
For EdU incorporation assays, colonic myofibroblasts and colon cancer cells (2.5x104 per 
well) were seeded and incubated overnight in FM followed by serum starvation for 48 h. 
Cells then were treated with GLP-2 or CM as appropriate for 24h. Proliferation was assessed 
by incorporation of 5-ethynyl-2’-deoxyuridine (EdU, 10 µM, 16h) and processing of samples 
using Click-iT (Invitrogen, Paisley, UK) and Alexa 568-azide. EdU positive cells were 
visualised on a Zeiss AxioCam HRM fluorescence microscope (Carl Zeiss, Welwyn Garden 
City, UK) on a 40x objective lens counting the total number of cell nuclei in 10 different fields 
using DAPI (Vector Laboratories, Peterborough, UK) (blue) and EdU positive nuclei.  
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Cell Counting Kit-8 assays (Dojindo Laboratories, Munich, Germany; the manufacturers use 
the abbreviation “CCK8” to describe these kits, but to avoid confusion with cholecystokinin 
octapeptide which shares the same abbreviation, we use the alternative contraction “CeCo” 
assays here) were performed on colonic myofibroblasts and cancer cells (8x103 per well) in 
96 well plates incubated overnight in FM followed by incubation with GLP-2 or CM medium 
in phenol red free SF medium for 72h. On the last day 10µl CeCo reagent was added to the 
wells and incubated for 2-4h as optimised for each cell type. Readings were taken at 450nm 
using a GenioPlus plate reader (Tecan, Zurich, Switzerland). 
 
Cell migration and invasion assays. Transwell migration and invasion assays were 
performed using BD inserts (Corning, New York, USA) as previous described (2.5 x 104 cells 
per insert) [39]. GLP-2 or CM were added in the lower well together with AG1024 
(Calbiochem, Darmstadt, Germany) as appropriate. Ibidi chamber (Ibidi GmbH, Martinsried, 
Germany) migration assays were performed in 24 well plates. Ibidi culture inserts were 
placed at the bottom of the wells followed by seeding of 105 cancer cells and 5x104 
myofibroblasts on separate sides of the insert. After 24h the insert was removed, leaving a 
500µm wound; cells were then treated with GLP-2 up to 42h and images taken with a 
Hamamatsu Camera (Hamamatsu Photonics, Hamamatsu City, Japan) at 0, 6, 24, 32, 42h 
using a Leica DMIRE2 microscope on a heated stage, humidified chamber (Solent Scientific, 
Portsmouth, UK); cells in the wound were counted in 5-8 fields per insert. 
 
qPCR. RNA was extracted in 1.25 ml Tri-Reagent (Sigma, Dorset, UK) according to the 
manufacturer’s instructions from control and GLP-2 treated colonic myofibroblasts. RNA 
pellets were re-suspended in 50 l of nuclease free water and 4 µg of RNA reverse 
transcribed with avian myeloblastosis virus reverse transcriptase and oligo-dT primers 
(Promega). Real time PCR was carried out using an ABI7500 platform (Applied Biosystems, 
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Warrington, UK) using TaqMan primer/probe sets (human IGF-1, IGF-2, GAPDH), Precision 
Plus 2x real time PCR master mix (Primer Design, Southampton, UK) and 5’-FAM, 3’-
TAMRA double dye probes (Eurogentec, Southampton, UK). All values were standardized to 
GAPDH. Assays included a no template control (NTC), and a standard curve as previously 
described [28]. Primers and probes were designed using Primer Express v3.0 (Applied 
Biosystems) and were purchased from Eurogentec (Seraing, Belgium). Probes for detection 
of human GAPDH, IGF-1 and IGF-2 cDNA were intron-spanning and were: GAPDH: 5’-GCT 
CCT CCT GTT CGA CAG TCA-3’(forward), 5’-ACC TTC CCC ATG GTG TCT GA-3’ 
(reverse),  5’-CGT CGC CAG CCG AGC CAC A-3’ (probe); IGF-1: 5’-TGT ATT GCG CAC 
CCC TCA A-3’ (forward), 5’-CT CCC TCT ACT TGC GTT CTT CA-3’ (reverse), 5’-ACA TGC 
CCA AGA CCC AGA AGG AAG TAC A-3’ (probe); IGF-2, 5’-CCG TGC TTC CGG ACA ACT 
T-3’ (forward), 5’-GGA CTG CTT CCA GGT GTC ATA TT-3’ (reverse), 5’-CCC AGA TAC 
CCC GTG GGC AAG TTC-3’ (probe). 
 
Western blotting. Cell extracts were prepared in RIPA buffer and media samples were 
concentrated with StrataClean resins (Agilent Technologies Ltd, Santa Clara, CA, USA) and 
processed for Western blotting as previously described  [28] using antibodies to IGFBP-3, 4, 
5 and -7, MMP-1, -2, -3 and -10 (R&D Systems) and GAPDH (Biodesign, Maine, USA). 
 
Statistics. Results were calculated as mean ± standard error of means (SEM). Student t-
test and ANOVA were performed on the data as appropriate with significance at p<0.05 
using Systat Software Inc. (London, UK) unless otherwise stated.  
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Results 
GLP-2 stimulates myofibroblast proliferation. In initial studies we showed that GLP-2 
produced a dose-related increase in EdU incorporation into CCD18 myofibroblasts (Fig 
1A,B). We then studied EdU incorporation by colonic CAMs and ATMs. As previously 
reported for gastric CAMs [19], basal EdU incorporation was greater in the colonic CAMs 
compared with the corresponding ATMs. In the presence of GLP-2 there was stimulation of 
EdU incorporation into both CAMs and ATMs and the response in the former was greater 
than the latter (Fig 1C). In a CeCo assay of cell growth, GLP-2 also stimulated colonic CAM 
growth and to a lesser extent that of ATMs (Fig 1D). 
 
GLP-2 stimulates myofibroblast migration and invasion. We then examined the actions 
of GLP-2 on CAM and ATM migration and invasion using Boyden chambers (Fig 2A,B). In 
both cell types, GLP-2 at a concentration that stimulated proliferation also stimulated 
migration and these responses were similar in CAMs and ATMs; moreover in both cases 
they were abolished by AG1024 which selectively inhibits IGF-1 receptor tyrosine kinase 
activity at the concentrations used [33]. Similarly, there was IGF-dependent stimulation of 
CAM invasion and in this case the response was significantly greater than that of ATMs. 
 
Myofibroblast conditioned medium stimulates epithelial cell proliferation. Consistent 
with a previous report that epithelial cells lines lack the capacity to respond to GLP-2 [25], 
there was no change in EdU incorporation (Fig 3A) by two of the epithelial cell lines used in 
the present study (SW480 and LoVo) in response to GLP-2 applied directly to the cells while 
there was a small effect on HT29 cells (Fig 3B). However, there was a small increase in EdU 
incorporation in response to CAM CM in SW480 cells that was enhanced by pre-treatment of 
myofibroblasts with GLP-2 and there were greater increases in EdU incorporation by HT29 
and LoVo cells in response to CAM CM, and in both cases there were small further 
increases using CM from GLP-2-treated myofibroblasts. In all three intestinal cell lines, the 
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responses to control CM and to GLP-2 CM were suppressed by AG1024 (Fig 3C). In CeCo 
assays of cell growth, there were robust responses by all three intestinal epithelial lines to 
control myofibroblast CM and small but significantly increases in response to GLP-2 
pretreatment of myofibroblasts (Fig 3D).  
 
Myofibroblast conditioned medium stimulates epithelial cell migration and invasion. 
When GLP-2 was applied directly to epithelial cells (SW480, HT29, LoVo) there was no 
effect on migration or invasion in Boyden chambers (Fig 4A). However, there was strong 
stimulation of migration of all three cell lines in response to control CAM CM and there were 
small but significant further increases in response to CM from GLP-2 treated myofibroblasts 
(Fig 4B). In each case the response was inhibited by AG1024. There were relatively modest 
increases in invasion of HT29 and LoVo cells in response to control myofibroblast CM but 
the response was strongly enhanced by GLP-2-treated CM; all responses were inhibited by 
AG1024 (Fig 4C). 
 
GLP-2 stimulates migration in co-cultures of epithelial cells and myofibroblasts. In 
view of the potential for cross-talk between epithelial cells and myofibroblasts we then asked 
whether the response to GLP-2 was preserved when these cells were co-cultured. For this 
purpose we used Ibidi chambers with myofibroblasts in one chamber and epithelial cells in 
the other so that subsequent removal of the insert yielded cultures of the two cells separated 
by 500 m (Fig 5A). Over a period of 42 h after removing the insert there was progressive 
migration of both cell types toward each other (Fig 5A). The numbers of migrating epithelial 
cells were roughly 10 times higher than those of myofibroblasts. Nevertheless at each time 
point examined from 6 – 42 h the presence of GLP-2 increased the migration of each of the 
epithelial cell lines and of the co-cultured CAMs (Fig 5B). 
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GLP-2 increases IGF-1 and IGF-2 transcript abundance. In view of the evidence that 
GLP-2 might act via IGF we first examined microarray data from myofibroblasts which 
indicated that both IGF-1 and IGF-2 were expressed in colonic CAMs and ATMs; the relative 
abundance of IGF-1 in colonic myofibroblasts was higher compared to IGF-2, while in gastric 
myofibroblasts IGF-2 was dominant [4]. We then used qPCR for both IGF-1 and IGF-2 to 
assess responses to GLP-2. At a concentration of GLP-2 (10 nM) that increased 
myofibroblast migration and proliferation, there was 1.8 ± 0.2 fold higher IGF-1 transcript 
abundance and 1.5 ± 0.2 fold higher IGF-2 transcript abundance.  
 
GLP-2 promotes IGFBP degradation in myofibroblasts medium. Since there is evidence 
that GLP-2 might act via IGFBP-4 [1] we examined by Western blot the profile of IGFBP-4 
and also of IGFBP-3, -5 and -7 in CAMs treated with GLP-2. In control media there were 
clear bands corresponding to intact IGFBP-4, -5 and -7 (Fig 6A), while IGFBP-3 was 
undetectable (not shown). There were also minor bands corresponding to degradation 
products of IGFBP4 (15 kD) and  IGFBP-5 (10-15 kD). In the presence of GLP-2 the bands 
corresponding to intact IGFBP-4, and -5 were maintained but there was increased 
abundance of the degradation products. In the presence of an inhibitor of MMP activity 
(GM6001, 10 M) the action of GLP-2 in promoting degradation of IGFBP4 and -5 was 
inhibited (Fig 6A). There was also an increase in IGFBP-4 and -5 in cell extracts in response 
to GLP-2 compatible with increased expression (Fig 6B). Multiple proMMPs are secreted by 
myofibroblasts (MMP-1, -2, -3 and -10) [18]. Of these, MMP-1 was increased in abundance 
in GLP-2 treated cells and media (Fig 6C,D) although there was little or no change in MMP-
2, -3 and -10. 
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Discussion 
The present study provides evidence that GLP-2 acts on cancer-derived myofibroblasts to 
stimulate their proliferation, migration and invasion. These effects are blocked by an inhibitor 
of IGF1 receptor tyrosine kinase and since there is an increase in IGF-1 and -2 transcript 
abundance as well as increased degradation of IGFBP-4 and -5, the data support the idea 
that the actions of GLP-2 on myofibroblasts are at least partly mediated by IGF. Consistent 
with previous findings, GLP-2 had little or no effect on three intestinal epithelial cell lines, but 
conditioned medium from CAMs stimulated proliferation, migration and invasion of these 
cells, and to varying degrees GLP-2 treatment of myofibroblasts enhanced the responses in 
an IGF-receptor dependent mechanism. The data add to previous work in this area by 
indicating (a) that GLP-2 might regulate myofibroblast numbers and motility, and (b) that 
myofibroblasts in cancer are putative targets for GLP-2. In view of the importance of 
myofibroblasts in determining the tumour microenvironment the data raise the prospect that 
GLP-2 might influence cancer progression.  
 
The importance of myofibroblasts as targets for the trophic action of GLP-2 in the intestine 
has been clear for some time [7, 32]. Previous work has made use of CCD18 myofibroblasts 
that are derived from normal infant intestine [7], mixed intestinal cell cultures [13] and 
intestinal sub-epithelial fibroblasts [29]. The present findings extend these studies to include 
myofibroblasts derived from colon cancer and adjacent tissue. For the most part previous 
studies have focussed on the mechanisms by which myofibroblasts influence epithelial cell 
growth. While the growth factor responses of the myofibroblasts themselves have received 
attention, less has been given to other aspects of myofibroblasts biology. The observation 
that GLP-2 increases myofibroblast cell number, and very likely cell position (via actions on 
migration/invasion), suggests a more dynamic system than previously supposed.  
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It is recognised that cancer-derived fibroblasts and myofibroblasts differ from their 
counterparts in normal tissue [9, 19, 31]. The different properties of CAMs may, at least to 
some extent, reflect epigenetic changes [22]. The differences are important given the 
emerging evidence that stromal cells in general [16], and myofibroblasts in particular, 
stimulate cancer progression [8]. Previous work has shown that in both gastric and 
oesophageal cancer, CAMs exhibit increased proliferation, migration and invasion compared 
with ATMs [19, 27]. The present study has shown that colonic CAMs similarly exhibit a more 
aggressive phenotype than colonic ATMs i.e. increased basal and stimulated proliferation 
and invasion in response to GLP-2. The fact that these cells retain the ability to respond to 
GLP-2 provides a mechanism by which GLP-2 might influence cancer progression [23]. The 
therapeutic value of GLP-2 in treatment of short bowel syndrome is now widely appreciated, 
but it would be as well to keep in mind that in some circumstances GLP-2 might have 
deleterious effects in influencing cellular microenvironments. A particularly clear example is 
provided by gastrointestinal stromal tumours that have been reported to express GLP-2R 
[26]; the possibility that GLP-2 may also act on colon cancers via their stromal component 
should now be considered.  
 
A number of growth factors have been proposed to mediate the actions of GLP-2 on 
myofibroblasts, including IGF [29], VEGF-A [7], KGF [32] and EGF-family members [3, 40]. It 
is important to be clear that these need not be mutually exclusive. Our data suggest that 
colonic CAMs stimulate epithelial cell growth, migration and invasion by an IGF-receptor 
dependent mechanism [37] that is enhanced to varying degrees by treatment of 
myofibroblasts with GLP-2. The increase in epithelial proliferation was modest, the migratory 
response was stronger and the invasive responses in two cells lines were very strong. High 
constitutive expression of IGF has already been reported [29] and would account for the 
present findings on intestinal epithelial cell proliferation and migration. In the case of the 
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strong invasion response of these cells we suggest that increased bioavailability of IGF as 
well as increased MMP-activity [18] might interact to enhance the response.  
 
There was increased transcript abundance of IGF-1 and IGF-2 in response to GLP-2 which 
would provide one mechanism to account for the biological responses of both epithelial cells 
and myofibroblasts. However, our data suggest that there are also likely to be other 
mechanisms. Secreted IGF is sequestered by IGFBPs. In gastrointestinal myofibroblasts the 
main IGFBPs include IGFBP-4, -5 and -7. Cleavage of IGFBP-5 by MMP-7 released by 
epithelial cells has previously been shown to increase the bioavailability of IGF-2 which may 
stimulate both epithelial and stromal cells [17]. In addition to regulating IGF bioavailability, 
some IGFBPs or their fragments, may exert independent biological activities [14, 20]. 
Recently, a role for IGFBP-4 in mediating the effects of GLP-2 was indicated by the 
observation that in mice null for IGFBP-4 the effect of GLP-2 was inhibited [1]. The precise 
cellular mechanisms remain uncertain, but it is interesting that in our studies GLP-2 
treatment of myofibroblasts increased the abundance of IGFBP-4 degradation products seen 
in western blot; there was a similar effect on IGFBP-5 but not IGFBP-7.  Moreover, there 
was an increase in cellular abundance of IGFBP-4 and -5 compatible with stimulation of 
expression by GLP-2 as previously reported [1]. The degradation of IGFBP-4 in other 
systems is attributable to PAPP-A which is a member of the pappalysin group of metzincin 
metalloproteinase [6]. The GLP-2 stimulated degradation of IGFBP-4 and -5 was blocked by 
a broad spectrum inhibitor of MMP activity, GM6001, which is reported to have little effect on 
pappalysins [15]. We found GLP-2 increased the abundance in media and cell extracts of 
proMMP-1 (although not proMMP-2, -3 and -10). We suggest therefore, that GLP-2 
increases the expression in myofibroblasts of IGFBP-4 and -5, and proMMP-1. Further work 
is now needed to determine the biological significance of the degradation products of 
IGFBP-4 and -5, particularly with respect to IGF binding and any potential biological activities 
independent of IGF.  
Shawe-Taylor, page 15 
 
The maintenance of tissue architecture is presumed to involve two-way interactions in vivo 
between myofibroblasts and epithelial cells. We attempted to design a simple in vitro model 
to establish whether the actions of GLP-2 on myofibroblasts, and those of myofibroblasts on 
epithelial cells, were preserved when the two cell types were in co-culture. The data 
obtained using Ibidi chambers indicate that the migratory responses observed when the two 
cells were cultured separately were preserved in co-cultures. Interestingly, though, the 
magnitude of the migratory responses by epithelial cells was considerably greater than that 
of myofibroblasts. Nevertheless the data allow us to conclude that any feedback mechanism 
from intestinal cells that might exist to limit the myofibroblast response to GLP-2 is relatively 
modest. 
 
Alongside an appreciation of the therapeutic benefits of GLP-2, there has also been an 
appreciation, based on data from animal models, that GLP-2 might have growth promoting 
effects with deleterious consequences in cancer [36]. Thus in two mouse models of 
carcinogen-induced colon cancer (dimethylhydrazine, azoxymethane) administration of GLP-
2 increased tumour size [21, 38], although in other models eg APCmin-/- mice, it had no effect 
[25]. Whether or not GLP-2 aggravates human colon cancer progression needs to be kept 
under review. The case for further studies of GLP-2 and human colon cancer is supported by 
the present data which raise the prospect that GLP-2 acts on human colon cancer-derived 
myofibroblasts to trigger pathways influencing myofibroblast number and motility and, 
indirectly, cancer cell function. It is worth stressing, that since the present data indicate that 
GLP-2 targets the IGF system in colonic myofibroblasts this system would presumably be 
susceptible to novel therapeutic strategies targeted at IGF-responsive cells in colon cancer 
[41].  
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Legends 
Fig 1. GLP-2 stimulates myofibroblast proliferation. A, Representative image of EdU labelled 
myofibroblast (filled arrow; unlabelled cells, open arrows). B, dose-response relationship for 
GLP-2 stimulation of EdU incorporation by CCD-18 cells (n = 4). C, GLP-2 (10 nM) 
stimulates EdU incorporation into both cancer-derived myofibroblasts (CAM, n = 6) and 
adjacent tissue myofibroblasts (ATM, n = 3). D, GLP-2 also increases cell growth measured 
by CeCo assay (n = 4). Horizontal arrows * p<0.05, ** p<0.01,  *** p<0.001.  
 
Fig 2. Stimulation of myofibroblast migration by GLP-2. A, GLP-2 (10nM) increases migration 
of both CAMs and ATMs in Boyden chamber chemotaxis assays and the response is 
reversed by an inhibitor of IGF1 receptor tyrosine kinase (AG1024, 20μM)(n = 3 – 6). B, 
similar data for invasion assays (n = 3). See Legend to Fig 1 for further details. 
 
Fig 3. GLP-2 enhances the increase in intestinal epithelial cell proliferation in response to 
myofibroblast conditioned media. A, Representative images of EdU (red) labelled HT29, 
SW480 and LoVo cells (nuclei stained blue with DAPI). B, GLP-2 (10 nM) has no direct 
effect on proliferation of SW480 or LoVo cells and a small effect on HT29 cells (n = 3). C, 
Conditioned media from myofibroblasts stimulates EdU incorporation in SW480, HT29 and 
LoVo cells: the responses are enhanced by previous treatment of myofibroblasts with GLP-2 
(10 nM) and are blocked by the IGF receptor inhibitor AG1024 (20 M)(n = 3 – 6). D, in 
CeCo assays myofibroblast CM stimulates growth of SW480, HT29 and LoVo cells and the 
effect is enhanced by prior treatment of myofibroblasts with GLP-2 (10 nM); GLP-2 alone 
has no effect (n = 3 – 4). See Legend to Fig 1 for further details. 
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Fig 4.   GLP-2 enhances the increase in intestinal epithelial cell migration and invasion in 
response to myofibroblast conditioned media. A, GLP-2 alone (10nM) has no effect on 
migration (left) or invasion (right) of SW480, HT29 or LoVo cells in Boyden chamber 
chemotaxis assays (n = 3). B, Conditioned media (CM) from myofibroblasts stimulates 
migration of SW480, HT29 and LoVo cells: the responses are enhanced by previous 
treatment of myofibroblasts with 10nM GLP-2 (GLP-2 CM) and are blocked by the IGF 
receptor inhibitor AG1024 (20 M)(n = 3 – 6). C, similar results for invasion assays (n = 3). 
See Legend to Fig 1 for further details. 
 
 
Fig 5. Mutual stimulation of migration by epithelial cells and myofibroblasts in co-cultures 
treated with GLP-2. A, Representative images of Ibidi chambers with CAMs on one side and 
either SW480, HT29 or LoVo cells on the other side; on the left is a schematic illustrating the 
experimental design; thereafter are images taken at 0, 6, 24, 32 and 42 h. At each time point 
epithelial cells are shown on the left and CAMs on the right; the box indicates the area in 
which cells were quantified. B, time course of responses measured as numbers of cells in 
the defined area migrating towards the opposite side in either control co-cultures, or treated 
with GLP-2 (10 nM). The data are shown for co-cultures of SW480 and CAMs (left), HT29 
and CAMs (centre), and LoVo cells and CAMs (right). In each case the data for epithelial 
cells are in the upper panel and CAMs from the corresponding co-culture in the lower panel 
(n = 3). See Legend to Fig 1 for further details. 
 
Fig 6. Western blots showing IGFBP-4, -5 and –7, and MMP-1, -2, -3 and -10 after GLP-2 
treatment of myofibroblasts. A, IGFBP-4, -5 and –7 in media of CAMs treated with GLP-2 
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(10nM, 24h) with or without the MMP-inhibitor GM6001 (10 M). B, similar data including 
GAPDH for corresponding cell extracts. C, MMP-1, -2, -3 and -10 in media of CAMs treated 
with GLP-2. D, MMP-1 and GAPDH in the corresponding cell extracts. Representative 
images from 4 independent experiments.   
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